2020 Council Election: Meet the Candidates

The online election is being managed by Simply Voting. IGCS Members with voting rights will receive a link to the online ballot from the email address, vote@simplyvoting.com starting on Sunday, April 5th and will receive weekly reminders to vote through May 5, 2020.

A link to the online ballot will also be posted here when the election opens on April 5th. Until then, please get to know the candidates and read their personal statements below.

President Elect

For the year 2020, the position of President Elect must be filled by a member residing in Asia or Oceania.
Prof. Keiichi Fujiwara was elected by nomination. Congratulations, Keiichi!

Keiichi Fujiwara, MD, PhD
Professor and Director, Dept. of Gynecologic Oncology
Saitama Medical University Int’l Medical Center

Specialty: Gynecologic Oncology

Read Keiichi's Election Profile

IGCS Activities:

  • IGCS Biennial Meeting Scientific Program Committee Co-Chair (Kyoto 2018)
  • IGCS Secretary-Treasurer (2012-2014)
  • IGCS Secretary-Treasurer Elect (2010-2012)
  • Senior Editor of the International Journal of Gynecological Cancer (2008-2013)
  • IGCS Finance Committee Member (2005-2007)

Personal Statement:

It is my great honor to have the opportunity to be a candidate for President-Elect position of IGCS.

I have been a member of IGCS since 1995, was a member of the Finance Committee from 2005 to 2007 and Secretary Treasurer of the Society from 2012 to 2014.  I have also served as a Senior Editor of the International Journal of Gynecologic Cancer from 2008 to 2013. The biggest opportunity for me so far to contribute to the Society was at the IGCS Annual Meeting held in Kyoto, Japan, 2018 as Scientific Co-Chair. During my career and with that experience, I have witnessed the impressive growth of IGCS and have also learned that IGCS is the number one society to connect the gynecologic cancer communities on a global scale.

My career as a gynecologic oncologist started by learning the importance of evidence-based medicine and then it advanced to learning evidence generating processes, especially in the planning and conducting of clinical trials. This process is important not only to establish the evidence for future patient care but also to improve the quality of daily practice. Building clinical trial infrastructure requires multidisciplinary collaboration with nurses and other co-medical staff to support and protect our patients. I strongly believe this experience has given me the opportunity to lead multidisciplinary committees such as those within the IGCS whose membership is diverse.

To achieve this purpose, I would like to propose that the IGCS enhances further collaboration with nursing and other healthcare professionals and more importantly with our patients, both of which the Society has recently started.

After almost two decades of learning about and being actively involved in clinical trials, I have recently had the opportunity to serve as Chair of the Gynecologic Cancer Intergroup, GCIG, which is the global network of clinical trial groups worldwide (October 2018 until October 2020). 

In the past, evidence generation has been performed mainly in developed countries where resources and the infrastructure support of clinical trials are well established. It is now necessary to ensure that clinical trial expertise is disseminated to other part of the globe to fit the evidences in those areas by considering the uniqueness and differences in ethnical and cultural backgrounds. 

The training of clinical trial specialists is the role of the clinical trial group. In contrast, the role of the IGCS is to spread the importance of clinical trials, encourage researchers who want to go down that path, and appeal to hospital managers and government officials about the importance of building infrastructure to support clinical trials. A strong partnership between IGCS and GCIG and particularly CCRN will ensure that women in low- and middle-income countries will receive all the benefits that an active clinical trial program produces.

During my experience working with a number of world-class leaders in the gynecologic oncology community, I have learned the importance of synergies generated by working together in a collegial and respectful fashion. As President of IGCS I would hope the international community of caregivers in women’s health will grow more closely together and that our patients will have improved outcomes as a result. It is my great honor to be considered for this position.

Candidates for Vice President

Michael Birrer, MD, PhD
Director, Winthrop P. Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
United States

Specialty: Medical Oncology & Translational Research

Read Michael's Election Profile

IGCS Activities:

  • Consistent reviewer for the International Journal of Gynecological Cancer
  • IGCS Biennial Meeting Scientific Program Committee Member (Bangkok 2008)
  • Invited Speaker, IGCS Annual Global Meeting (Rio de Janiero 2019)

Personal Statement:

I have dedicated my professional life to the diagnosis and treatment of women with gynecologic cancers. Caring for woman suffering from these diseases has been a great satisfaction for me.  In addition, this effort has included running a fully funded genomics laboratory along with a consistent focus on translating these results into the design and activation of “cutting edge” clinical trials.  Many of these projects involve large consortiums of national and international collaborators unified by a mutual interest in understanding the molecular underpinnings of gynecologic cancers and ultimately helping women with these diseases.

My administrative experience includes a broad and deep experience in participating in and leading many national and international committees and organizations focused on gynecologic cancers. This includes the Gynecologic Cancer Intergroup Committee, Society of Gynecologic Oncology, Cancer Research UK, Department of Defense Ovarian Cancer Research Program, and American Society of Clinical Oncology to name a few. These experiences mean that I have worked with many of the investigators in the field and they are familiar with my abilities and style. My leadership style is best described as inclusive, collaborative and supportive. It is critical that the best and innovative researchers are always given a chance to participate and that we encourage and support our young investigators. 

It would be a great honor for me to serve on one of the premier professional organization focused upon gynecologic cancer patients. I would hope to help spread IGCS’s message and expand its mission particularly to underserved populations throughout the world. My background as both a medical oncologist and translational researcher would help bring a different viewpoint and novel approach to the leadership of the group. A strong effort to engage and encourage laboratory based researchers would be very important for IGCS. In many ways, the future of the field is dependent upon translation laboratory research into novel drug discoveries. These are two areas that I have extensive experience in and I would be delighted to promote within the organization.

Jae-Weon Kim, MD, PhD
Professor and Director, Gynecologic Oncology Center
Seoul National University
Republic of Korea

Specialty: Gynecologic Oncology

Read Jae-Weon's Election Profile

IGCS Activities:

  • Member of the Scientific Program Committee at 16th and 18th IGCS Meetings (Lisbon 2016; Rome 2020)
  • Senior Editor, International Journal of Gynecological Cancer (2008-2018)
  • Attended and presented at 6th, 10th, 11th, 13th, 14th, 15th, 16th, and 17th IGCS Biennial Meetings

Personal Statement:

As a devoted member of the IGCS for the last 23 years, I would be honored to be elected as Vice President to assist in the further development of the organization. Since the 6th IGCS meeting held in Fukuoka in 1997, I have served as not only a member of the scientific program committee but also as a Senior Editor for the IJGC from 2008 to 2018. I have been proactively involved with the Gynecologic Cancer InterGroup (GCIG) as a representative of the Korean group since 2004. In addition, I have been served for more than 10 years to the Asian SGO as a Council member, Treasurer, and Editor-in-Chief of the ‘Journal of Gynecologic Oncology’ and am currently active as President-Elect.

During my career, I have come to realize that there are plenty of unrevealed and unmet needs in the gynecologic field, especially in underdeveloped countries. Considering the variety of needs and available resources in different areas, as well as the diversity of each social and clinical environment, we need to develop more refined localized approaches to help out our colleagues and women suffering from gynecologic cancers. With international collaboration and communication with mutual respect between members of the IGCS, we can make a significant change and I would like to serve as a bridge between IGCS and several regional societies to make this possible.

I would also like to contribute in the enhancement and optimization of international collaboration for clinical studies among members of the IGCS. To achieve scientific excellence, frontier researches should be promoted and the exchange of knowledge between multidisciplinary researchers worldwide should be facilitated in an efficient and enjoyable way. This should especially be possible in young gynecologic oncologists, especially those studying in developing areas. I would like to create more innovative approaches for these young researchers by expanding overseas training opportunities and scholarships, which are supported by the IGCS and other donors.

If I were elected as Vice President of the IGCS, I would do my best to support the activities of the President and Council members and would definitely spend my time and energy to serve the Members and Society, and keep achieving the IGCS mission worldwide.

R. Wendel Naumann, MD
Professor and Director of Research in Gynecologic Oncology, Associate Medical Director of Clinical Trials
Levine Cancer Institute, Atrium Health, Charlotte, NC
United States

Specialty: Gynecologic Oncology

Read Wendel's Election Profile

IGCS Activities:

  • IGCS Annual Global Meeting Scientific Program Committee Member (Rome 2020)
  • Organizer and Moderator of the IGCS LiveStream Gynecologic Cancer Update (2019)
  • Project ECHO® Virtual Tumor Board Contributor (2018-Present)
  • IGCS Biennial Meeting Scientific Program Committee Member (Vancouver 2012)

Personal Statement:

The IGCS is now the primary organization for education in gynecologic oncology worldwide.  I have a long commitment to educational leadership in the care of women with gynecologic malignancies and want to continue my service within the IGCS. 

I have served on the clinical practice committee for the SGO and later the education committee, ultimately becoming the chair of the education committee. I have served on the executive board for the SGO as well as the program committee for SGO and IGCS five times. In addition, I have organized multiple meetings including serving as the co-director of the SGO winter meeting for the past five years.   Last year I organized a LiveStream meeting for the IGCS that was broadcast to over 300 people in 88 countries. The LiveStream effort is ongoing, and we are excited about our current project which will be a joint surgical symposium and film festival in conjunction with AAGL for this spring.  I have also been involved with international outreach as part of a joint NCI/IGCS education mission to improve screening for cervical cancer in Belarus and Kazakhstan and have hosted two international fellows at our institution.

My involvement has made me realize that that efforts in education within the IGCS can have a major impact on the care of women with gynecologic malignancies throughout the world and this continues to fuel my passion for these educational efforts.  As the IGCS continues to grow and expand, we will have a greater opportunity to reach more members to positively impact the care of women with gynecologic malignancies. I am committed to finding new ways to educate and allow our members to interact and learn from each other. My hope is that we can expand education on palliative care as major effort to relieve suffering, improve access to genetic testing, as well as continue to update our membership on the latest developments in cancer, even if our members cannot attend the annual meeting.  To do this we will need to find better ways to communicate and educate our constituents. 

In addition, I would like to develop case-based learning curriculum for both common and rare gynecologic malignancies and continue to expand opportunities for surgical training and mentorship.  It is clear to me that IGCS is in the position to have a major impact on global care of women with gynecologic malignancies and complex gynecologic surgical problems and I very much want to be a part of the leadership of this organization.

Candidates for Secretary-Treasurer Elect

Vivek Arora, MD
Consultant Gynaecological Oncologist
Prince of Wales Private Hospital, Sydney

Specialty: Gynecologic Oncology

Read Vivek's Election Profile

IGCS Activities:

  • IGCS Council Member Representing Asia/Oceania (2016-2020)
  • International Mentor, IGCS Gynecologic Oncology Global Curriculum & Mentorship Program for Hamad Medical Corporation Women’s Hospital, Qatar (2019-Present)
  • IGCS Global Network (Online Member Community) Moderator (2018-2019)
  • IGCS Mentorship & Training Committee Member (2018-Present)
  • IGCS Visiting Scholar & Mentorship Program Chair (2018-Present)
  • Project ECHO® Virtual Tumor Board Contributor (2018-Present)
  • Organizer of IGCS & ASGO Visiting Scholars Program for the 2014 IGCS Biennial Meeting in Melbourne
  • Panelist, “Training and Career Development in Gynecologic Oncology” at the inaugural Shingo Fujii Young Doctors Summit at the 2012 IGCS Biennial Meeting in Vancouver

Personal Statement:

As a gynaecological oncologist who has trained and worked across 3 continents, I have been privileged to witness how the specialty has grown over the last 2 decades. I have also witnessed, from close quarters, the disparity that still exists in different parts of the world. Advances in treatment options for gynaecological cancer benefit a lot of women, but also further highlight these disparities.

As a Council Member of the IGCS over the last 4 years, my focus has been to further the goals of IGCS in international collaboration, mentorship and support to the centers with limited resources or those with newly established gynaecological oncology programs. As a member of the IGCS Mentorship and Training Committee I have been involved with the Project ECHO outreach multi-disciplinary team meetings in gynaecological oncology and chairing the Visiting Scholar and Mentorship Program.

I feel that there is more that I can contribute to the Society and our common goals. During my term as a Council Member I have been fortunate to be a part of the tremendous growth in the Society, in membership numbers and its global presence. I seek your support for the position of Secretary-Treasurer Elect because I believe that I will be in a position to complement the efforts of the incoming IGCS Council. I have the organizational skills and the attention to detail that is required for this important role in the Society.

Hennie Botha, MBChB, MMed, FCOG, PhD
Associate Professor
Stellenbosch University and Tygerberg Hospital
South Africa

Specialty: Gynecologic Oncology

Read Hennie's Election Profile

IGCS Activities:

  • IGCS Council Member Representing Africa/Europe/Middle East (2014-2018)
  • IGCS Regional Meeting Organizing Committee Chair (Cape Town 2014)
  • IGCS Global Curriculum & Mentorship Program Exam Committee Member (2018-Present)
  • IGCS Scientific Publications Committee (2018-Present)

Personal Statement:

The IGCS strives to unite the global community in eliminating the suffering caused by gynaecological cancers. I firmly believe international collaboration leads to the exchange and improvement of knowledge and skills, creates space for collegial support, and generates energy for progress.

I have worked in low-, middle-, and high-income countries and appreciate the challenges and opportunities of each environment. I believe people, with their attitudes and skills, are more important to success than highly advanced facilities or medicines. The IGCS is an ideal vehicle to promote linkage and solidarity amongst all of us working with people affected by cancer.

I have been a member of the IGCS for almost 20 years. My experience on the council from 2014 to 2018 and committees of the Society helps me to understand the complexity and excitement of international communication and collaboration.

The dynamic focus on education and internationalisation over the last few years created a rapid expansion of programs which calls for steady financial management. The leadership of the IGCS must ensure careful stewardship of the resources available without limiting the development agenda. There needs to be a balance between financial prudence and spending responsibly for future growth and development.

I am committed to the healthy future of the IGCS and all its members.

Rainer Kimmig, MD
Full Professor
West German Cancer Center, University of Duisburg-Essen

Specialty: Gynecologic Oncology

Read Rainer's Election Profile

IGCS Activities:

  • IGCS Council Member Representing Africa/Europe/Middle East (2016-2020)
  • IGCS Annual Global Meeting Scientific Program Committee Chair (Rome 2020)
  • IGCS Global Network (Online Member Community) Moderator (2018-Present)

Personal Statement:

Dear IGCS members and friends all around the world,

I would like to serve as your Secretary-Treasurer Elect in IGCS and ask you for your support.

As Council Member for the past 4 years I have had the opportunity to get insights into our Society, its achievements and also its potential for the coming years. I also had the chance to actively support the development of our online communication platform and our new membership directory. 

As you know, I am convinced that each of us should have the very best education and technology available. Thus, the main goal of IGCS projects must be to share knowledge and skills all around the world and bring those on the best possible level  for everyone. This must be accompanied by evaluating the chances to implement modern technology according to each country’s resources and to develop specific skills to compensate for lack of technology wherever possible.

Thus, for the Secretary-Treasurer it is crucial not only to ensure a healthy economical/financial situation of the society, but also to support the projects most suitable to achieve these goals. This will bring the Society into a bright future being the world’s leading voice in gynecologic oncology with a powerful impact on womens’ health.  I would be very happy if I could further contribute to this promising future of the Society with all my experience and my heart beating for IGCS.

Before being elected for the IGCS Council, I worked 6 years in the ESGO Council as “Educational Chair” and Vice President. Currently, I am serving as President of SERGS (Society of European Robotic Gynaecological Surgery) after 6 years experience as Council Member and Secretary/Treasurer.

Dear friends, please give me your trust and confidence; I will work hard for you and our Society.

Health, Luck and Happiness to all of you.

Yours, Rainer

Candidates for Council Member (Americas)

Carolyn Johnston, MD
Clinical Professor Emeritus
University of Michigan
United States

Specialty: Gynecologic Oncology

Read Carolyn's Election Profile

IGCS Activities:

  • International Mentor, IGCS Gynecologic Oncology Global Curriculum & Mentorship Program for St. Paul Millennium Medical College and Black Lion Hospital in Addis Ababa, Ethiopia (2017-Present)
  • Project ECHO® Virtual Tumor Board Contributor  (2018-Present)

Personal Statement:

I feel that it is my turn to be of service to an organization that has given so much support to the fellows whom I mentor and admire. These fellows have either benefitted from membership in an IGCS sponsored fellowship and its attendant assets (Ethiopia) or from IGCS-sponsored travel and visiting scholar grants (Ghana). Thus, so too have I gained from the IGCS. I also believe, that although it is great to have a diverse and large membership, that individual members need to work together to build a sustainable product, particularly in locations where quickly the mentee becomes the mentor for the next batch of trainees. How to continue to provide that support while moving on to new locations is a challenge, but one worthy of attention.

I, like others, have spent decades in one location (Kumasi, Ghana) helping to build a sustainable future for gynecologic oncology training. This continuity has allowed me to understand many of the political, economic, social and personal challenges of being a gynecologic oncology fellow in the developing world, where one cannot simply stop every day medical work and dedicate all their time to specialty training, but must also continue to support the department as a generalist and teacher of medical students and residents, as well as work in a private practice setting to support themselves. Training and teaching in this environment have taught me patience and humility, enriched my teaching skills and given me great friends and colleagues. In addition, I have taught and trained many fellows in a gynecologic oncology fellowship program at an academic institution in the USA for 30 years which requires a different and more complex, and perhaps more rigid, approach to training. This apparent dichotomy gives me a unique understanding of international needs and possibilities. I was also fortunate to be a contributing member of the Sister Society which helped to develop the curriculum that is now used in the IGCS sponsored fellowships.

Given that I am primarily retired, working only one week a month while also continuing to travel to Ethiopia and Ghana for fellowship-related teaching, I have more time to devote to the IGCS council, should I be selected. I have significant past leadership and not-for-profit advisory board member experience (Michigan Cancer Consortium, ACS Great Lakes Division Board of Directors, ECHO tumor board) and work well in groups as a team member. I am however not reluctant to take the lead if a situation requires it, and I appreciate being continually challenged.  This all said, it would be a privilege to be elected to the council.

Mario Mendes Leitao, Jr., MD
Attending Surgeon
Memorial Sloan-Kettering Cancer Center
United States

Specialty: Gynecologic Oncology

Read Mario's Election Profile

IGCS Activities:

  • IGCS Annual Global Meeting Scientific Program Committee Member (Rio de Janeiro 2019; Rome 2020)
  • IGCS Biennial Meeting Scientific Program Committee Member (Lisbon 2016)

Personal Statement:

My passion is to cure women with gynecologic malignancies. As an individual physician and surgeon, one can only directly impact a small number of women. The only way to truly make a difference in the care of women with gynecologic cancers around the world is through strong and fruitful relationships among the many colleagues who care for these women. I have dedicated my life to not only helping the women that I see but also to sharing whatever knowledge I may have with as many colleagues as will be interested to hear. This can only be done through international dialogue and discussions. I have been fortunate to have been invited all over the world to share my thoughts and knowledge with others.

However, it is I that have learned so much more from the privilege I have been given to learn from the experience of so many talented physicians and non-physicians from every part of the world. As Chair of the Membership Committee for the SGO, it was my primary goal to expand the membership to as many International colleagues as would want to join. The SGO Members voted to adopt the historic membership criteria changes that we developed in the membership committee which made it possible for International colleagues to join easily.

I have sponsored numerous colleagues from around the world to come and observe at our institution, including UICC fellows. I am fellowship director of the only established, continuous, and fully structured International Fellowship in Gynecologic Oncology in the United States. I can take my prior experience, passion for international collaboration and the friendships I have made of so many colleagues around the world to enhance the work of the IGCS which has already made tremendous progress in the advancement of care of women around the world. I also value International collaboration from a personal standpoint. My parents are both immigrants from Portugal and the majority of my family is in Portugal and Brazil. I have been honored with a Membership in the Surgical Oncology Society of Brazil.

Michael Pearl, MD
Professor, Gynecologic Oncology
Stony Brook Medicine
United States

Specialty: Gynecologic Oncology and Palliative Care

Read Michael's Election Profile

IGCS Activities:

  • IGCS Education Committee Member, Palliative Care Work Group Co-Chair (2017-Present)
  • Project ECHO® Virtual Tumor Board Contributor (2018-Present)

Personal Statement:

While we have come far with our ability to care for our patients, we all too often still fail to meet our patients’ goals. As I’ve matured as a physician, I’m increasingly focused on improving the overall quality of life for women with gynecologic malignancies. Within my institution, I serve in a variety of leadership roles, allowing me the opportunity to develop programs addressing gaps in care and improving clinical and research services. Nationally, I serve on several committees focused on improving the provision of palliative care & hospice for women with gynecologic malignancies.

Annually, 1.3 million women develop a gynecologic malignancy worldwide, half of whom die; 56% of cases and 64% of deaths are in lesser developed countries.  Only 14% of adults who need palliative care receive it; 78% of those who need it are in lesser developed countries. Palliative care is a human rights issue; the World Health Assembly called upon the WHO and Member States to improve access to palliative care as a core component of health systems.

The purpose of IGCS includes “improvement in the quality of life” for women with gynecologic malignancies. Arguably, effective palliative care provides the greatest improvement in our patients’ quality of life, yet 70% of our members report no formal training in palliative care. There is a critical need to educate our members, as well local health care providers, in the principles of palliative care.

In 2018, I was given the privilege to serve as the co-editor of the IGCS Global Curriculum for Palliative Care. Working with a passionate and dedicated team, we developed a superb curriculum that will serve as a template to introduce practicing health care providers, primarily those in lesser developed countries, to the knowledge and skills necessary to provide effective palliative care and improve the quality of life for women with gynecologic malignancies.

International medicine, especially in lesser developed countries, has been a lifelong goal that I’ve deferred due to personal and professional constraints.  At this time in my life and career, I’m able to commit to international service. My work with IGCS members and leadership has been thoroughly enjoyable, rewarding and the highlight of my career.

Should I be elected to the IGCS Council, I will strive to assist the council and leadership in representing the IGCS membership and the women cared for by the members.  I believe that my experience as a senior gynecologic oncologist, palliative care specialist and seasoned administrative leader provides a unique perspective that will greatly benefit IGCS. In particular, I will work with IGCS to improve the provision of palliative care to those in need, especially in lesser developed countries.

My many years of clinical, research and leadership service, including serving on the equivalent of the IGCS Council, have given me substantial experience as a collaborative committee member and leader. It’s been a privilege and a pleasure to work with the members and leadership of IGCS; I welcome the opportunity to continue to do so as a Council member. 

Candidates for Council Member (Asia/Oceania)


Rhonda Farrell, BAppSc (Physio) DRANZCOG MBBS (Hons) FRANZCOG CGO MSurg  
Chris O’Brien Lifehouse, Royal Prince Alfred Hospital, University of Sydney

Specialty: Gynecologic Oncology

Read Rhonda's Election Profile

IGCS Activities

  • Presented at IGCS Biennial Meetings (Prauge 2010; Melbourne 2014)

Personal Statement:

I have been an IGCS Member since 2005. All women and their families deserve the highest standard of care for the prevention, detection and treatment of gynaecological cancer independent of where they live or their socio-economic situation.  Medical caregivers in wealthy countries have an obligation to assist those in poorer nations to provide this care through education and mentorship, new technologies, and financial support.

As a member of the IGCS Council, I would like to not only improve my own participation in these activities but to reach out and engage others to do the same. My best leadership qualities are my ability to engage the wider community to recognize these goals and support them through philanthropy, to mentor junior doctors and other colleagues to improve the quality of gynaecological surgery, and to foster and support research into gynaecological cancer.

I work well in a team as a driver of change and as a collaborator to support other members of the team to work to the best of their ability.  I have particular interest and experience in the following areas 1. fostering collaboration between surgical disciplines (gynaecological oncology and other oncological surgical specialties) to improve the standard of teaching of junior surgeons and to enhance the overall multidisciplinary care of women with abdominopelvic cancer, 2. supporting, mentoring and promoting collaboration between junior surgeons, oncology trainees and scientists in gynaecological cancer research, 3. working with young women in the community to engage them in careers in science, technology, engineering and medicine (STEM), and 4. engaging with consumers and the wider community to foster philanthropy and support improvements in cancer care. Through working with IGCS, I would like to expand these skills and apply them on an international platform to improve outcomes for all women with gynaecological cancer.

Dilyara Kaidarova, MD, PhD
Director, Kazakh Institute of Oncology and Radiology

Specialty: Gynecologic Oncology

Read Dilyara's Election Profile

IGCS Activities:

  • Kazakhstan Representative for the IGCS Strategic Alliance Partnership (2017-Present)
  • Project ECHO® Virtual Tumor Board Contributor (2018-Present)

Personal Statement:

Kazakhstan is the leading country among the CIS countries in the implementation of the National Cervical Cancer Screening Program and the HPV vaccination program. I have been the Director of the Kazakh Institute of Oncology and Radiology for the past four years. The main objective is to improve the quality of cancer care in Kazakhstan. Numbers of programs have been initiated to improve the quality of Cancer Care under Kazakh Institute of Oncology and Radiology leadership. The ImPACT Mission Review of Cervical Cancer Screening Program was initiated in Kazakhstan. In the result of these we improved cervical cancer screening coverage of the target population.

Why am I running for Council Member practicing in Asia?

The main purpose of my work as an IGCS Council Member will be to attract gyn-oncologists from Kazakhstan’s neighboring countries to the IGCS. Kazakhstan has just begun to take steps to cooperate and collaborate with international medical societies. These partnerships opened the opportunity for Kazakhstan to develop evidence-based medicine in the cancer care area, learn from the experience of foreign colleagues, and participate in international research and projects. I hope that Kazakhstan will become a bridge in the cooperation of the countries of Central Asia with the leading specialists of IGCS.

Joining the post of council will strengthen the work on the prevention of cervical cancer not only in Kazakhstan, but also in Central Asia. The work will be carried out to attract international studies as well as training specialists from neighboring countries.

Asima Mukhopadhyay, MD, PhD, MRCOG, MSc
Consultant Gynecological Oncologist
Chittaranjan National Cancer Institute Kolkata, India
Northern Gynecological Oncology Centre, Gateshead, United Kingdom

Specialty: Gynecologic Oncology

Read Asima's Election Profile

IGCS Activities:

  • IGCS Education Committee Member, General Gynecologic Oncology Workgroup (2018-Present)
  • International Mentor, IGCS Gynecologic Oncology Global Curriculum & Mentorship Program for Civil Service Hospital, Nepal (2018-Present)

Personal Statement:

My professional career has prioritised:

  1. Promoting education and training in low-middle income countries (LMICs-India/Nepal) including development of cytoreductive and minimal access surgery programs. I currently supervise two Nepalese trainees in the Global Curriculum Programme.
  2. Translational/clinical research with focus on developing low-cost biomarkers and interventional trials suited for the need for women residing in LMICs. I have been able to successfully develop and lead a co-operative research group – Kolkata Gynecological Oncology Trials and Translational Research Group (KolGoTrg) which is the first ever group from India to be represented in GCIG. We have 3 CCRN sites and hope to build up a network in ovarian cancer (OCRN) keeping in mind the increasing trend globally. The royalty that I receive, being one of the co-inventors of the PARP inhibitor rucaparib has been donated to support this work.

While working in India and the UK and mentoring the IGCS global curriculum in Nepal, my reflection is that many gynecological oncology regional centers in Asia/Oceania currently may not have access to a structured program as robust and inclusive as the IGCS module even if there are local board-certified programs.  

As an IGCS Council Representative from Asia-Oceania, my role will be:

  1. Expanding the IGCS curriculum especially in LMICs/sites which cannot obtain local accreditation due particularly to the number of positions although otherwise fulfilling the IGCS criteria. All regional cancer centers may be eligible to become IGCS certified as well if they opt for and fulfill the standards/criteria. With an increase in the number of sites, it may not be possible for one person/central IGCS organization to co-ordinate this effort and we may have to have region specific leaders who will develop tumor boards/training sessions/international mentoring in a more time-zone/cost-efficient manner. One example being the India-Nepal partnership. However, there is need for developing “training the trainers” modules and short courses/travelling fellowships for the trainers as a pre-requisite to this expansion so that the quality and parity is ensured between regions.
  2. I would promote development of an IGCS certified nursing training program and courses/mentorship schemes for health care assistants/social workers working in the field of gynecological cancers.
  3. I will develop a minimal dataset (through a data harmonization committee and determination of standards/ audit trail for data quality) for data capture for women presenting with symptoms/referral patterns and treatment/defaults/outcomes/ survival trends. This could be based on databases like REDCap. Centers participating in this scheme and maintaining a track record for prospective and periodic data capture for at least 2 years will be certified as IGCS data centers and have incentives towards participation at IGCS meetings. Members in each region can be identified to lead on this responsibility. This will improve membership/retention/local empowerment.
  4. I will promote publications of grey literature/structured reports/audits from regional centers through the IGCS education portal (divided in region specific sections and templates) and journals like Gyn Oncology Reports. Fellows/young scientists and clinicians will be encouraged to promote clinician-scientist interactive forums.

It is an honour to be considered for this position.

Candidates for Council Member (Europe)

Donal Brennan, PhD
Professor of Gynaecologic Oncology
University College Dublin

Specialty: Gynecologic Oncology

Read Donal's Election Profile

IGCS Activities:

  • IGCS Annual Global Meeting Scientific Program Committee, European Regional Co-Chair (Rio de Janeiro 2019)
  • IGCS Education Committee Member, General Gynecologic Oncology Workgroup (2019-Present)
  • International Mentor, IGCS Gynecologic Oncology Global Curriculum & Mentorship Program for University of West Indies, Jamaica (2018-Present)
  • Course Director, Shingo Fujii Young Doctors Summit (Melbourne 2014; Lisbon 2016; Kyoto 2018)

Personal Statement:

The IGCS is a truly global society and its activity in both the developing and developed world are what makes serving as a Council Member so attractive. The opportunity to have a global impact on policy, training, and ultimately improve outcomes for all women affected by gynaecological cancer irrespective of their geographical location are the main reasons I would like to serve on the IGCS Council. My own experience in addressing serious concerns around HPV vaccination and cervical screening in Ireland have allowed me to develop a collaborative leadership approach with politicians, patients, and the public.

If elected, I would focus on developing even closer links to patient advocates.  Many problems in medicine arise from poor communication.  I firmly believe that as medical technology advances, communication with patients and their families will become more challenging. I believe the only approach to address this issue is to incorporate patient experience and shared vocabularies into clinical and research practices.  Technologies such as next generation sequencing and personalised medicine are developing at an astonishing rate, however cultural narratives around illness and medicine do not have the same agility; for example, while we may intervene at a genetic level to treat a cancer using a PARP inhibitor, we do not have a word for parents who have lost a child. As a consequence, there is a communication gap between the capacity of medicine and its delivery. Patients and doctors are literally not speaking the same language.  

Therefore, if elected, I would work on developing meaningful and lasting partnerships with international patient advocates form a variety of geographical regions. The goal of this partnership would be to develop an international shared vocabulary for women with gynaecological malignancy. As a truly international society, the IGCS is uniquely positioned to develop this kind of resource which would have a major impact on the daily practice of its members but would also provide a lasting resource for women all over the world with gynaecological cancer. 

Daniela Luvero, MD
University Campus Bio Medico of Rome

Specialty: Gynecologic Oncology

Read Daniela's Election Profile

IGCS Activities:

  • Active participant in IGCS Meetings since 2010
  • Collaborated with the IGCS to plan workshops, conferences, and presentations for the IGCS Biennial Meetings (Lisbon 2016; Kyoto 2018) and the Annual Global Meeting (Rio de Janeiro 2019: Rome 2020)

Personal Statement:

My name is Daniela Luvero and I have always been interested in Gynecologic Oncology. It was a great privilege and honor to have been recently nominated for the position of Council Member for Europe.

I have been devoted to Gynecologic Oncology for my whole life. In 2013, I was a clinical fellow in the Gynecologic Oncology Unit at University College Hospital in London under the supervision of JA Ledermann, participating in research protocols and clinical activities. I am currently in the PhD Oncology course, following research on the early diagnosis of ovarian cancer.

Since 2010, I have been an active participant in IGCS meetings, and from 2015 onwards I have collaborated in IGCS planning workshops, conferences and presentations. I have participated in round tables, have served on the industry advisory board and have spoken at national and international conferences. I am a contributing author to several national and international papers regarding the prevention, treatment, and study of gynecologic cancer, with a specific attention to quality-of-life.

Most of my work has been dedicated to advocacy programs, collaborating with several national and international patients’ associations. I endeavor to ensure that all people impacted by cancer are empowered through knowledge, strengthened by action, and sustained by community, through online, in-person, and phone-based counseling and support groups and through educational workshops and publications.

As an IGCS Council member, I would like to offer my experience in survivor-patient advocacy programs and contribute to women’s empowerment globally, especially in low-income countries, to improve women’s understanding of cancer prevention, risks, screening tests and treatments. I would also leverage my youth to meaningfully engage young doctors in the work of the IGCS.

If I were selected it would be my honor to contribute to improving advocacy- and community-centered programs and to engage survivors-patients, caregivers, families, and advocates globally.

Lukas Rob, MD, PhD
Department of Obstetrics and Gynecology, 3rd Medical Faculty, Charles University Prague, Oncogynecology Center University Hospital Kralovske Vinohrady
Czech Republic

Specialty: Gynecologic Oncology

Read Lukas' Election Profile

IGCS Activities:

  • IGCS Finance Committee Member (2006-2010)
  • IGCS Biennial Meeting Scientific Program Committee, President of Local Organizing Committee (Prague 2010)
  • IGCS Nominating Committee Member (2015-2016)

Personal Statement:

With the nomination and possible election to the IGCS Council as the representative of oncogynecologists for the European region, I would like to contribute with my work experience to the further development of the society and to help achieve well-set strategic goals.

From my point of view, the most important effort is to achieve optimal care in women with gynecologic malignancies in individual regions of the world, to help build infrastructure of oncogynecological care according to real local possibilities.

In particular I see possibilities in improving education, training programs, and sharing experience with building infrastructure of oncogynecological care. These programs must be organized in cooperation with local societies and leading physicians. I will be honored to contribute with my work in the further development of IGCS.

Candidates for Council Member (Radiation Oncology)

Thomas Samuel Ram, MD
Professor & Associate Director (Missions)
Ida B Scudder Cancer Center, Christian Medical College Vellore

Specialty: Radiation Oncology

Read Thomas' Election Profile

IGCS Activities:

  • IGCS Education Committee Member, Radiation Oncology Work Group (2019-Present)
  • IGCS Travelling Scholar Recipient (2008)

Personal Statement:

I have been an Active Member of IGCS since 2006, and I feel privileged to have received generous support and guidance from IGCS for my early career development which enabled invaluable global exposure to oncology. I had the honour of being awarded the IGCS travelling scholar award in 2008 which supported my training for Cervix brachytherapy at Long Beach Memorial Hospital, California.

Over the past several years I have been involved in various national and international activities, recently involving WHO, IGCS, and International Cancer Expert Corps (ICEC) which has added a global perspective professionally and personally. I feel this opportunity will enable me to contribute globally with the experience and skill I have gathered through my international engagement. Serving on the IGCS Council will provide an opportunity to utilise my talents in health care leadership, global networking and my experience serving in a not-for-profit academic institution and in underserved areas.

If I am elected, I would like to demonstrate effective stewardship of this role and responsibility. I would like to develop a strategy to further the impact mandate of IGCS – Educate, Collaborate, Unite, Mentor. I would like to address issues that will bridge the global health gaps, especially in gynaecological oncology by developing appropriate strategies for resource-stratified education and training – thus enabling high quality, affordable cancer care.

I would also like to develop health care models as the future of health care is transitioning to a shifting paradigm of care shift and role shift. This paradigm will perhaps be the solution for filling the gaps in the oncology care value chain where work force shortage of oncology professionals is already leading to significant health care disparities. I believe this will be one of the key strategies if we need to strengthen the interdependence within various health care professionals in our health care value chain, especially as we seek to implement the Global Strategy for Elimination of Cervical Cancer as envisioned by the WHO.

I have been fortunate to be mentored into health care leadership as early as my medical school days in the early 1990s. I had the privilege of leadership experience especially in underserved areas and in not-for-profit academic organisations which has placed me at a unique position of thinking from a perspective of lean health care in oncology. The vision of our institution CMC Vellore of compassionate clinical care, educational, and research excellence in sustainable systems has enabled me to experience a passionate commitment to the most vulnerable people while at the same time promoting cutting-edge education, service, and research.

Due to my visits to international cancer centres and interaction with several global oncology leaders, my networking strengths will be appropriately useful through this responsibility. My ongoing training in MBA (Health Care Systems and Hospital Management) will also add value to the role as an international representative of the Radiation Oncology community in IGCS. I believe that this responsibility will provide an opportunity on a global platform for a fulfilling experience as an oncologist as it will enable meaningful global partnerships towards effective cancer care.

Alexandra Taylor, MD
Royal Marsden Hospital, London
United Kingdom

Specialty: Radiation Oncology

Read Alexandra's Election Profile

IGCS Activities:

  • IGCS Annual Global Meeting Scientific Program Committee Member (Rio de Janeiro 2019)
  • Project ECHO® Virtual Tumor Board Contributor (2019-Present)

Personal Statement:

I would like to serve as a member of the IGCS council because this would be a great opportunity to become more involved in developing excellence in care for women with gynecological cancer. The IGCS multi-disciplinary approach is essential for optimising outcomes and supporting education, research and healthcare with a global focus. I bring enthusiasm, commitment and a strong collaborative approach, with experience of working within national and international committees. My areas of particular interest are radiotherapy development, training and patient survivorship.

I believe the international collaboration that exists within IGCS provides opportunities to further develop education and training in radiation oncology. My research background has included development of internationally adopted guidance on radiotherapy target volumes. I have developed and led IMRT workshops and national radiation oncology meetings on gynaecological cancer. The rapid pace of recent developments in radiation oncology offers exciting opportunities to improve outcomes for patients. But to support these advances we require robust validation and quality assurance, particularly as new techniques including stereotactic radiotherapy, re-irradiation and combination therapies with immunotherapy are increasingly being used.

Radiotherapy is an essential primary treatment for cervical cancer globally and there remains a huge need to improve the available resources in many countries. IGCS has already developed a successful international mentorship program for gynecology oncology surgery and I would aim to promote a similar program for training and mentorship in radiation oncology.

In addition, with the significant improvements we are making in cancer treatment, we now have increasing numbers of long-term survivors. Treatment effects can have a significant impact on the quality of life for patients. Survivorship programmes and management of the consequences of treatment is an important field of patient care that I am keen to highlight within IGCS.

A Message from Dr. Roberto Angioli on COVID-19

IGCS President, Prof. Roberto Angioli speaks about the Coronavirus from his office in Rome.

Transcripts of the message are available in the following languages: English, Italian, Arabic, Chinese, Japanese, Portuguese, and Spanish.


COVID-19 Resources & a Message from our President

COVID-19 Resources

COVID-19 & Cancer 

In the News

Connect with Others: IGCS Member Community

Visit the IGCS Social Link Discussion Forum created for Members to discuss issues and share resources related to COVID-19.

IGCS President, Prof. Roberto Angioli speaks about COVID-19 from his office in Rome.

Transcripts of Prof. Angioli’s message are available in the following languages: English, Italian, Arabic, Chinese, Japanese, Portuguese, and Spanish.

Visiting Scholar Applications Due March 31

IGCS International Visiting Scholar & Mentorship Program

Program Details
The Visiting Scholar & Mentorship Program will provide financial support for one (1) early career gynecologic oncologists residing in low- and middle-income countries to travel to an established gynecologic oncology unit for a minimum of two (2) months and a maximum of three (3) months to receive advanced training, foster a relationship with their mentor and gain experience, knowledge, and skills to implement within their local institution and practice. Training must be completed during the calendar year of 2020.
We are now accepting applications through March 31st!

Those interested in participating in the program should review the eligibility criteria and application material requirements carefully. We expect that this will be an extremely competitive application process.

Eligibility & Application Requirements
The applicant, proposed host mentor and the head of the applicant’s current institution must submit information for the application to be complete.

Download the application for complete details regarding eligibility and application requirements.

Applicants that do not meet the eligibility requirements and late applications received after 23:59 hours (11:59 P.M.) CST on the 31st of March 2020, will not be considered.

The applicant must be a currently active IGCS member for two consecutive years and the proposed host mentor must be a currently active IGCS member in their third year of membership.

If you have any questions, please contact IGCS Membership Manager, Cathy Fearing at cathy.fearing@igcsdev.com.

Education Highlight: IGCS-IJGC Interactive Learning Articles

Education Highlight: Interactive Learning Articles

A New Offering from the IGCS Education Committee: IGCS-IJGC Interactive Learning Articles

We are excited to announce that the IGCS Education Committee’s Work Group on Gynecologic Cancer has developed a new interactive learning feature that allows members to test their knowledge while reading select articles published in the International Journal of Gynecological Cancer.

Work group leader, Dr. Paul Cohen (Australia) developed a series of multiple choice and true/false questions related to key concepts within the first selected article.

Visit the IGCS Member Education Portal to download the first IGCS-IJGC Interactive Learning Article:

Lower extremity lymphedema in patients with gynecologic malignancies
January 7, 2020
Authors: Kimberly Dessources, Emeline Aviki, Mario M Leitao Jr

Dr. Cohen says he is “excited to assist the IGCS Education Committee in developing new and relevant ways to use content especially from our journal – The International Journal of Gynecological Cancer. We hope that these interactive learning articles will improve retention of knowledge and enhance readers’ educational experience. I am very grateful to Dr. Pedro Ramirez, Editor in Chief of the International Journal of Gynecological Cancer, for assisting with selection of appropriate articles.”

When reading the Interactive Learning Article, test your comprehension by answering a series of questions.

The correct answer is highlighted on the following slide.

This resource has been developed by members of the IGCS Education Committee General Gynecologic Oncology Work Group and they will be creating more interactive learning articles throughout the year.

We hope that these interactive articles will increase learner engagement and make learning fun.

We would like to thank Dr. Pedro Ramirez, Editor-in-Chief of the International Journal of Gynecological Cancer, BMJ Publishing, and all the authors of the selected papers, for their generosity in making these articles available to IGCS members.

We hope you enjoy them and have fun learning!


IGCS-EMAS Position Statement on Managing Menopause

The open access joint statement was published in the International Journal of Gynecological Cancer February 12, 2020.

European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis

Authors: Margaret Rees, Roberto Angioli, Robert Coleman, Rosalind M Glasspool, Francesco Plotti, Tommaso Simoncini and Corrado Terranova

Worldwide, it is estimated that about 1.3 million new gynecological cancer cases are diagnosed each year.

Management of menopausal symptoms and the prevention and treatment of osteoporosis in women with gynecological cancer needs to be individualized, with or without menopausal hormone therapy, according to tumor type and stage, and the woman’s age.

In women who are taking anti-estrogenic therapies such as aromatase inhibitors, estrogen-based therapies are contraindicated and non-hormonal options are recommended as initial therapy.

Gynecologic Oncology News & Press

A compilation of articles, news, study results and other updates in the field of gynecologic oncology.

Entries with titles highlighted in red may be of particular interest to survivors, caregivers or the general public.

PARP Inhibitor Becomes Standard of Care for Advanced Ovarian Cancer Subset
February 7, 2020: Oncology Nursing News – Frontline niraparib (Zejula) is the new standard of care for patients with newly diagnosed, platinum-sensitive advanced ovarian cancer, after the positive results from the phase III PRIMA trial, explained Antonio González-Martín, MD, lead author in the study. Read more.

World Health Organization Outlines Plan to Eliminate Cervical Cancer in Low to Middle Income Countries
February 5, 2020: Cure – The World Health Organization (WHO) has announced its plans for eliminating cervical cancer as a public health problem among low-income to middle-income countries by fully vaccinating 90% of girls by 15 years old, screen 70% of women between the ages of 35 and 45 and provide 90% of patients with disease receiving care. The organization believes not only will this eliminate cervical cancer in these regions within this century, but also prevent millions of deaths, according to two modeling analyses published in The Lancet. Read more.

MEK/PI3K Inhibitor Combo Generates Activity in RAS/BRAF-Mutant Ovarian Cancer
February 4, 2020: Targeted Oncology – Continuous dosing of the MEK inhibitor binimetinib (Mektovi) plus buparlisib (BKM120), a PI3K inhibitor, demonstrated promising activity as treatment of patients with ovarian cancer harboring either a RAS or BRAF mutation, according to results from a phase Ib clinical trial (NCT01363232). Read more.

ASCO Guideline: Germline Testing Recommended for All Women Diagnosed With Epithelial Ovarian Cancer
February 4, 2020: Cancer Therapy Advisor – A retrospective study showed improved survival among patients with ovarian cancer treated with beta-
All women with a diagnosis of epithelial ovarian cancer should be offered testing for specific germline mutations, according to a new recommendation from ASCO. Read more.

Cervical cancer elimination ‘could be achieved’ by 2120
February 3, 2020: Healio – High HPV vaccination coverage for girls and scaled-up screening and treatment may lead to the elimination of cervical cancer in most lower-middle-income countries over the next 100 years, according to results of two modeling studies published in The Lancet. Read more.

Women’s wellness: researchers look at post menopause as key factor in endometrial cancer
February 3, 2020: Medical Xpress – Endometrial cancer is the most common gynecological malignancy in the U.S. and the fourth most common cancer among women. In addition, endometrial cancer incidence rates are on the rise in the western world, suggesting that alterations in environmental factors such as diet, lifestyle, and the vaginal microbiome may be important drivers in its cause. Read more.

Ipilimumab Shows Tolerability and Signals Efficacy in Advanced Cervical Cancer
January 28, 2020: Targeted Oncology – The phase I study of sequential ipilimumab (Yervoy) after chemoradiotherapy as a curative-intent treatment of patients with node-positive cervical cancer included 34 female patients with stage Ib2 to VI cervical cancer with positive pelvic lymph nodes, para-aortic lymph nodes, or both. Read more.

Use of intrauterine devices may decrease risk for ovarian cancer
January 21, 2020: Healio – Previous studies have linked the use of intrauterine devices (IUDs) to reduced risk for cervical and uterine cancer. Based on these findings, Saketh R. Guntupalli, MD, associate professor and director of the division of gynecologic oncology at University of Colorado School of Medicine, and colleagues examined the possible correlation between IUD use and risk for ovarian cancer. Read more.

Is it still reasonable to offer MIS hysterectomy? No.
January 20, 2020: Contemporary OB/GYN – Dr. Amanda Nickles Fader discusses the con side of the MIS argument from the LACC trial controversy. Read more.

Is it still reasonable to offer MIS hysterectomy? Yes.
January 20, 2020: Contemporary OB/GYN – Dr. Wendell Nauman discusses the pro side of the MIS argument from the LACC trial controversy. Read more.

While survival rates soar for other cancers, funding gaps limit progress on cervical and uterine cancer
January 10, 2020: The Verge – There are limited treatment advances for aggressive forms of these diseases. Read more.

Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
January 9, 2020: Cancer Therapy Advisor – The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Read more.

Now Accepting Abstracts for IGCS 2020

Submit your Abstracts for IGCS 2020

Submission Deadline: May 1, 2020

IGCS is seeking all medical professionals who are a part of the gynecologic and breast cancer care team to submit abstracts for the 2020 Annual Global Meeting of the International Gynecologic Cancer Society which will be held in Rome, Italy from September 10 – 12, 2020.

We are currently accepting abstracts to be considered for oral or poster presentation. All abstracts must be original work, and not previously published or orally presented at other scientific meetings. Select posters will be chosen as oral presentations for the featured poster session: “Walk the Posters with a Professor” in the exhibit hall.

Surgical film submissions will be accepted from April 1 – May 15.

Abstract Topics:

Basic/Translational Science
Genetics And Epidemiology
Gynecologic Pathology/Cytology & Disease Pathogenesis
Cervical Cancer
Uterine Cancer Including Sarcoma
Ovarian Cancer
Rare Tumors & Gestational Trophoblastic Neoplasia
Vulvar & Vaginal Cancer

Early Phase Clinical Trials
Trials In Progress
Symptom Management/Supportive Cancer Care
Nursing & Health Care
Global Health
Surgical Techniques & Perioperative Management
Surgical Films
Pre-Invasive Disease
Palliative Care

Click Here To Submit

If you have questions or need assistance, please email igcs2020@mci-group.com.

IGCS & WOCC Join Forces


Announcing a Strategic Advocacy Partnership Between the International Gynecologic Cancer Society and the World Ovarian Cancer Coalition

It is my pleasure to announce a Strategic Advocacy Partnership between the International Gynecologic Cancer Society (IGCS) and the World Ovarian Cancer Coalition (WOCC). This partnership maximizes the collective influence, membership, force, and reach of these two premiere organizations and establishes a framework through which they will provide tangible benefit to gynecologic cancer survivors-patients worldwide, with special emphasis on ovarian cancer.

Established in 2016, WOCC is a not-for-profit organization with 145 patient advocacy organization partners in 37 countries. WOCC works to ensure that every woman diagnosed with ovarian cancer has the best chance of survival and the best quality of life possible, wherever she may live. Its mission aligns perfectly with that of the IGCS of enhancing the care of women with gynecologic cancer worldwide. Uniting the globe in the fight against gynecologic cancers since 1985, IGCS currently has over 3,200 members in 115 countries. The membership of both organizations encompasses low-, middle-, and high-resource countries, consistent with their commitment to global health equity.

Elisabeth Baugh, Chair of the World Ovarian Cancer Coalition, explains, “As the largest global ovarian cancer patient advocacy network, the World Ovarian Cancer Coalition is committed to making a difference to the lives of all women affected by ovarian cancer. This strategic partnership creates a powerful global advocacy movement, uniting and strengthening patient and clinical voices to act as a force for urgent change. It is our firm belief that we will achieve much more together.”

With each organization retaining its independence, focus, and governance and with each committed to mobilizing outstanding global leadership, experts, and advocacy to reduce the burden of gynecologic cancers globally, this partnership does indeed represent a formidable force for change.

Emphasizing the importance of advocacy partnerships, IGCS President Roberto Angioli notes, “This partnership with the World Ovarian Cancer Coalition is representative of our commitment to working collaboratively with advocates worldwide to ensure best outcomes for all women and families affected by gynecologic cancers. We will continue to partner with local, regional, and global advocacy groups across all gynecologic cancer sites. These partnerships are essential to our mission.”

And, specifically, in activating this partnership, we will

  • Launch the WOCC’s Global Ovarian Cancer Charter—a call-to-action to all involved in the care of ovarian cancer survivors-patients—during the 2020 IGCS Annual Global Meeting in Rome.
  • Convene cancer site-specific partnership meetings and other forums that support the IGCS-initiated Global Advocacy Network focused on gynecologic cancers.
  • Integrate into IGCS, WOCC, and other international meetings, our individual organization-specific, mission-driven programming that supports advocacy broadly.

Together, IGCS and WOCC will amplify the global voices of gynecologic cancer survivors-patients and will prompt and accelerate change that expands awareness and options, improving survival rates and survivorship. To manage joint initiatives, each organization has a dedicated partnership lead—Dicey Jackson Scroggins, IGCS Director of Global Outreach & Engagement, and Clara MacKay, WOCC Executive Director.

We are well positioned to take on the challenges and excited by the opportunities to benefit women and families—wherever and under whatever circumstance they might live.


Mary Eiken, MS
IGCS Chief-Executive Officer

Gynecologic Oncology News Archive 2019

A compilation of articles, news, study results and other updates in the field of gynecologic oncology.

Entries with titles highlighted in red may be of particular interest to survivors, caregivers or the general public.

Experts Address Breast Cancer Relapse on AI Therapy During Targeted Tweet Chat
December 31, 2019: Targeted Oncology – During a Targeted Oncology tweet chat, Erika P. Hamilton, MD, director of the breast cancer and gynecologic cancer research program, and Stephanie Graff, MD, associate director of the breast cancer research program at Sarah Cannon Research Institute, discussed treatment options and considerations for the case of a patient with estrogen receptor (ER)-positive, HER2-negative breast cancer who relapsed on letrozole (Femara), an aromatase inhibitor (AI). Read more.

Proton Therapy Significantly Lowers Risk of Side Effects for Cancer Patients
December 26, 2019: SciTechDaily – Proton therapy leads to significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared with traditional radiation, while cure rates between the two groups are almost identical. Read more.

Preventing cervical cancer – an opportunity for Kenyans
December 13, 2019: Standard Media Co. – The Ministry of Health has decided to provide every girl in Kenya with Human Papilloma Virus (HPV) vaccination when she reaches the age of 10, following the introduction of the vaccine by President Uhuru Kenyatta last month. More than 800,000 girls will be vaccinated every year. Read more.

Breast-conserving treatment without surgery not supported at this time
December 13, 2019 – EureAlert! – Results from NRG Oncology’s BR005 study show that breast-conserving treatment without surgery cannot be recommended, based on the study criteria of clinical complete response, radiological complete response (rCR)/near rCR, and negative tumor bed biopsies. Read more.

10-year results of NRG Oncology/NSABP B-42 trial
December 12, 2019: EurekAlert! – Extended letrozole therapy improves disease-free survival (DFS) in postmenopausal women with HR+ breast cancer. Read more.

‘CA-125 is a valuable tool’ for women with ovarian cancer symptoms
December 11, 2019: Healio – CA-125 is a “useful test” for ovarian cancer in primary care, especially in symptomatic women aged older than 50 years, according to a presenter at the recent National Cancer Research Institute Cancer Conference in Glasgow. Read more.

CURE’s Clinical Trial Corner: Cervical Cancer Edition
December 9, 2019: Cure – Patients with cervical cancer and their caregivers should be aware of the various clinical trials being conducted in this disease space – particularly those they can possibly join. Here, CURE® has rounded up some of the clinical trials in cervical cancer that are currently enrolling across the country. Read more.

An Immunologist’s Journey To Get An Ovarian Cancer T Cell Therapy Into Clinical Trials
December 5, 2019: Clinical Leader – Powell sought and received support from ACGT in 2017. The three-year grant allowed him to develop and launch the trial, which makes it more likely that he will find other funding now, once the trial clearly demonstrates that it could work, safely. “Someone has to take a gamble that these approaches will be successful,” he says. Read more.

Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis
December 4, 2019: The Lancet – WHO has launched a Global Initiative to scale up preventive, screening, and treatment interventions to eliminate cervical cancer as a public health problem during the 21st century. Therefore, our study aimed to assess the existing burden of cervical cancer as a baseline from which to assess the effect of this initiative. Read more.

Patients with Endometrial Cancer Pose High Risk of Dying from Cardiovascular Disease
December 2, 2019: Cancer Network – A study published in the European Heart Journal suggested that patients with endometrial cancer pose a very high risk of dying from cardiovascular diseases (CVD) in the first year after diagnosis, supporting early involvement of cardiologists for patients with endometrial cancer. Read more.

Many cancer patients interested in pathology consultations
November 26, 2019: Medical Xpress – When surveyed, a majority of cancer patients expressed interest in participating in a patient-pathologist consultation program, according to a study recently published in the Archives of Pathology & Laboratory Medicine. Read more.

Secondary Cytoreduction Fails to Improve OS in Phase III Ovarian Cancer Study
November 21, 2019: Targeted Oncology – Overall survival was not improved with secondary cytoreduction followed by chemotherapy compared with chemotherapy alone in the phase III GOG-0213 trial, which missed its primary endpoint. Read more.

Questions Over Value of Bevacizumab in Many Cancers
November 20, 2019: Medscape – The antiangiogenic agent bevacizumab (Avastin, Roche/Genentech) is approved for use in six different types of tumor, but most of these approvals are based on improvements in progression-free survival (PFS), not overall survival (OS). Read more.

At-Home Urine Test Could Replace Pap Smear for Cervical Pre-Cancer Screening
November 13, 2019: Cure Today – A new non-invasive, at-home urine test and vaginal swab could soon replace the pap smear as the gold standard for detecting cervical pre-cancer, according to new study results presented at the National Cancer Research Institute’s (NCRI) 2019 Cancer Conference in Glasgow, UK. Read more.

Patients Must ‘Be In Tune’ With Bodies to Recognize Immunotherapy Side Effects
November 12, 2019: Cure Today – It is key for patients with lung cancer who are being treated with immunotherapy to be aware of the treatment’s potential side effects, although rare, and if symptoms appear to be worsening, according to Beth Eaby-Sandy. Read more.

Examining Genomics in the Treatment of Cervical Cancer
November 12, 2019: Cure – Could targeted therapy play a larger role in the treatment of cervical cancer in the near future? Researchers from Yale Cancer Center believe they are one step closer to finding out, according to new study findings published in the Proceedings of the National Academy of Sciences. Read more.

In Advanced Solid Tumors, MK-5890 Shows Promising Safety Results as Monotherapy or in Combination with Pembrolizumab
November 10, 2019: Targeted Oncology – The anti–CD27 agonist, MK-5890, demonstrated acceptable safety findings when administered as monotherapy and in combination with pembrolizumab (Keytruda) in numerous solid tumors. Read more.

Why Are Uterine Cancer Rates Rising So Drastically in Black Women?
November 6, 2019: SELF – Here’s a look at the data, plus symptoms to know. Read more.

More Frontline PARP Indications Are Expected in Ovarian Cancer
November 7, 2019: Targeted Oncology – PARP inhibitors (PARPi) are increasingly relevant for frontline maintenance indications and potentially in combination with chemotherapy for treatment-naïve ovarian cancer, including for those with BRCA-wildtype disease. Read more.

PARP Inhibitors Center Stage for Ovarian Cancer
October 7, 2019: Medscape – “I think the main message is that more women can benefit from having a PARP inhibitor in the first-line setting as maintenance treatment beyond those women with the BRCA mutation.” Read more.

A promising treatment for ovarian cancer
October 7, 2019: Kaiser Permanente – 5 Questions for…Dr. Michael A. Bookman, co-leader of a clinical trial that could provide an important new treatment option for women with advanced gynecological cancers. Read more.

Experts in Oncology Highlight Key Abstracts Presented at the 2019 ESMO Congress
October 7, 2019: Targeted Oncology – Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Read more.

New Evidence for Hyperbaric Therapy for Late Radiation Cystitis
October 4, 2019: Cancer Network – Hyperbaric oxygen therapy can relieve symptoms of late radiation cystitis in patients who underwent radiotherapy of the pelvic region for prostate cancer. Read more.

How three women trusted their instincts and discovered they had cancer
October 3, 2019: ABC News – By the time Sandra Hoehler was diagnosed with cancer, it was as much a moment of relief as one of fear. Read more.

What You Need to Know About Preventing Gynecologic Cancers
October 3, 2019: CURE – Knowing your family history is the first preventative step any woman can take to avoid a diagnosis of ovarian cancer. Read More.

Avelumab active in mismatch repair-deficient endometrial cancer
October 3, 2019: Healio – Avelumab induced promising activity among women with mismatch repair-deficient endometrial cancer regardless of PD-L1 status. Read more.

Patients Die While Docs on Hold
October 3,2019: Medpage Today – It shouldn’t take medical practitioners hours by phone to reach a knowledgeable person who can fairly review an appeal about a patient’s coverage. And, for gynecological cancers, that review should be made by oncologists familiar with cancer treatments, not by the pharmacist who happens to be on call that day. Read more.

More accurate diagnosis for rare ovarian cancer type
October 3, 2019: Medical XPress – The researchers found that the new biomarker—when it’s used in combination with another, established marker—increased the accuracy of the diagnosis. Read more.

How the new test for cervical cancer works – and why you should have it
October 2, 2019: The Sydney Morning Herald – What testing do you need to get done to avoid cervical cancer? Can treatment ruin your sex life? And what happens if the test shows that you have cancer? Read more,

Geography Determines Access to Palliative Care
October 2, 2019: Health Leaders – Access to and quality of hospital-based palliative care in the United States has more to do with geography than need, a new state-by-state report card finds. Read more.

Let’s Talk About Cancer Prevention and the Power of Support
October 2, 2019: Cure – “Most days, I feel empowered by the knowledge of my BRCA mutation. I encourage others to learn their family health history and to seek genetic counseling, if appropriate.” Read more.

Niraparib Shows “Impressive” Survival Improvements in Advanced Ovarian Cancer
October 2, 2019: Cancer Network – Maintenance therapy with niraparib (Zejula) showed a significant progression-free survival (PFS) benefit for patients with newly diagnosed advanced ovarian cancer in the randomized phase 3 PRIMA trial, regardless of homologous recombination deficiency status. Read more.

Breast Cancer Death Rate Continues to Drop, But Black Women Have Far Higher Mortality Rates
October 2, 2019: Forbes – Between 2013 and 2017, the death rate from breast cancer was 40% higher in black women than in white women, despite a slightly smaller incidence of breast cancer in black women. Read more.

Rising Obesity and Declining Fertility Linked with Increasing Breast Cancer Cases in U.S
October 2, 2019: Newsweek – A decades-long decline in breast cancer deaths in the U.S. has started to slow, while diagnosed cases of the condition have increased slightly—a trend that scientists believe could be partly caused by the obesity epidemic and declining fertility. Read more.

Hysterectomy May Raise Depression and Anxiety Risk
October 1, 2019: New York Times – Women who have a hysterectomy may be at increased risk for depression and anxiety. Four to six percent of women will develop depression or anxiety. Read more.

Pressure BioSciences’ Proprietary PCT Platform Fills Pivotal Role for Tumor Analyses in Novel Workflow Presented at Leading Global Gynecologic Cancer Meeting
October 1, 2019: Global Newswire – Data from Analysis of Cancer Tissue Proteins Generated from Novel Workflow Could Lead to Improvement in the Clinical Management of Gynecological Cancers. Read more.

Novel immunotherapy combination could provide fresh hope for patients with cervical cancer
September 30, 2019: News Medical – This cohort paired nivolumab with ipilimumab for the treatment of patients with recurrent or metastatic cervical cancer, with or without prior systematic therapies, and irrespective of PD-L1 expression. Read more.

Trametinib Tx Shows Promise in Tough-to-Treat LGSOC
September 30, 2019: MedPage Today – Trametinib treatment was associated with better outcomes in women with recurrent or progressive low-grade serous ovarian or peritoneal cancer versus treatment with standard-of-care chemotherapy. Read more.

Nivolumab-ipilimumab combination benefits women with advanced cervical cancer
September 30, 2019: Healio – “This is the most exciting data we have ever seen [among women] with metastatic cervical cancer,” R. Wendel Naumann, MD, professor and associate director of gynecologic oncology at Levine Cancer Institute at Atrium Health. Read more.

‘I Beat a Rare Form of Ovarian Cancer Twice—But I’m Still Doing Chemo’
September 30, 2019: Yahoo – Rose Marie Jackey is sitting in her hospital bed at Mount Sinai Hospital in New York City awaiting her monthly chemotherapy infusion treatment she’s been getting each month for the past three years. Read more.

Fertility-Sparing Surgery Equally Effective as Radical Surgery in Early Stage Ovarian Cancer, Study Finds
September 30, 2019: Ovarian Cancer News Today – Surgical treatment aimed at preserving fertility is just as effective, in terms of survival, as more aggressive surgery in treating early-stage ovarian cancer. Read more.

Immunotherapy in combination points to paradigm shift in the treatment of cervical cancer
September 30, 2019: Medical Xpress – With an estimated 570,000 cases and 311,000 deaths in 2018 worldwide, cervical cancer currently ranks as the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women. Read more.

Trauma-Informed Care Emphasizes Healthcare as a Partnership
September 30, 2019: Medpage Today – With so many women experiencing trauma in their lifetime, clinicians should take a patient-centered approach to care. Read More.

Addition of M6620 to gemcitabine prolongs PFS in platinum-resistant ovarian cancer
September 29, 2019: Healio – “Platinum-resistant ovarian cancer is associated with poor prognosis and represents an important unmet medical need.” Read more.

Veliparib regimen extends PFS in newly diagnosed high-grade serous ovarian carcinoma
September 29, 2019: Healio – The addition of veliparib to frontline chemotherapy followed by maintenance with veliparib monotherapy significantly prolonged PFS among women with newly diagnosed, high-grade serous ovarian carcinoma. Read more.

Niraparib significantly extends PFS in newly diagnosed advanced ovarian cancer
September 28, 2019: Healio – Niraparib significantly extended PFS among women with newly diagnosed advanced ovarian cancer, according to results of the randomized phase 3 PRIMA study presented at European Society for Medical Oncology Congress. Read more.

Ovarian cancer: more women benefit from maintenance combined targeted therapy
September 28, 2019: European Society for Medical Oncology – New data shows the benefit of a more intensive maintenance regimen for ovarian cancer with the PARP inhibitor olaparib added to bevacizumab, in an all-comers population, with and without a BRCA mutation. Read more.

First-Line Combo Boosts PFS in Advanced Ovarian Cancer
September 28, 2019: Medpage Today -Dual maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin) significantly improved progression-free survival (PFS) in women with newly diagnosed advanced ovarian cancer, as compared with single-agent bevacizumab. Read more.

Good News For Women With Newly-Diagnosed Ovarian Cancer
September 28, 2019: Survivor Net – A specific PARP inhibitor called Zejula more than doubled the amount of time that many women with ovarian cancer lived without their cancer getting worse. Read more.

Cediranib plus olaparib effective, safe for recurrent, platinum-resistant ovarian cancer
September 28, 2019: Healio – The combination of cediranib and olaparib appeared to be effective and safe for women with heavily pretreated, platinum-resistant ovarian cancer. Read more.

Results of the VELIA Trial in Ovarian Cancer
September 28, 2019: Targeted Oncology – Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer. See more.

PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
September 27, 2019: News Wise – Study shows that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival (PFS) for patients with newly diagnosed, metastatic high-grade serous ovarian cancer. Read more.

What Women Should Know About the FDA’s Endometrial Cancer Combination Approval
September 23, 2019: CURE – Women with endometrial cancer that is not categorized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who are not eligible for curative surgery or radiation, and whose disease has progressed after previous systemic therapy now have a new, and much needed, treatment option. Read more.

Nivolumab May Induce Promising Efficacy Outcomes in Certain Gynecologic Malignancies
September 23, 2019: Cancer Network – Treatment with nivolumab demonstrated promising efficacy results among patients with recurrent/metastatic cervical and vaginal or vulvar cancers. Read more.

Study Shows Niraparib Extends Time Without Symptoms, Toxicity in Ovarian Cancer
September 20, 2019: Oncology Nursing News – Treatment with niraparib (Zejula) improved survival and extended the time without symptoms or toxicity among patients with recurrent ovarian cancer, according to study results published in the Journal of Clinical Oncology. Read more.

Here’s Why Ovarian Cancer Is So Hard to Diagnose, According to a Doctor
September 20, 2019: Prevention – Ovarian cancer is often referred to as “the silent killer” for a good reason: It ranks as the fifth deadliest cancer among women. In fact, of the 22,530 women who will receive an ovarian cancer diagnosis each year, nearly 14,000 of them will die from it. Read more.

Can Recurrent Ovarian Cancer Patients Avoid Chemotherapy?
September 20, 2019: Cancer Network – The combination of niraparib and bevacizumab significantly improved progression-free survival compared with niraparib alone in a phase II study of patients with platinum-sensitive recurrent ovarian cancer. Read more.

Dr. Gunderson on the GOG-252 Trial in Advanced Ovarian Cancer
September 19, 2019: Onc Live – Camille C. Gunderson, MD, assistant professor of gynecologic oncology, Stephenson Cancer Center, discusses the phase III open-label GOG-252 trial (NCT01167712) in advanced ovarian cancer. See more.

Dr. Moore on Research Evaluating Repeat Exposure to PARP Inhibition in Ovarian Cancer
September 19, 2019: Onc Live – In the prospective phase II Evolve study, Stephanie Lheureux, MD, and her colleagues took women who had progressed on a prior PARP inhibitor and evaluated one of the reported mechanisms of acquired resistance to PARP with combination therapy. Read more.

Guest columnist: Writer shares ovarian cancer diagnosis, treatment
September 17, 2019: The State Journal – Quite honestly, I did not know much about this type of cancer when I first heard the term “ovarian” in November. Since that time, my knowledge about ovarian cancer has increased as I am now up close and personal with a Stage IV diagnosis. Read more.

My Surprising Experience with Ovarian Cancer
September 11, 2019: Thrive Global – This is my story with ovarian cancer and I share it in hopes of helping someone that experiences similar emotions, though not necessarily the same diagnosis or situation. Read more.

Scientists call for population-wide BRCA testing for higher risk group
September 11, 2019: Medical Xpress – Researchers are calling for population wide BRCA testing in the Jewish community after finding it to be more effective than current approaches, cost effective and had a high satisfaction rate with those undergoing testing. Read more.

Encouraging Responses Seen with TIL Therapy in Advanced Cervical Cancer
September 4, 2019: Targeted Oncology – Investigators set out to determine the safety and effectiveness of the TIL therapy in patients with advanced disease who have received at least one prior line of chemotherapy. Read more.

Surgeons remove 55-pound ovarian tumor from Russian patient, report says
August 28, 2019: Fox – A medical team in Russia has shared photos from a mind-boggling procedure last week that saw them remove a 55-pound tumor that had been growing in a patient’s pelvis. Read more.

Pain Associated With Quality of Life and Survival for Patients With Recurrent Ovarian Cancer
August 27, 2019: Oncology Nurse Advisor – For patients with recurrent ovarian cancer (OC), pain is associated with both quality of life (QOL) and overall survival. Read more.

Will advances in AI lead to more effective screening practices for ovarian cancer?
August 25, 2019: Healio – Screening techniques for ovarian cancer are nonexistent. Studies have looked at combinations of blood markers and ultrasounds, but they did not show a survival improvement. Ultimately, if a patient undergoes screening, it should lead to some improvement in outcome or prevention of the cancer altogether. Read more.

Remaining Ever Vigilant in Cancer Screening
August 20, 2019: CURE – Three years ago, I received a call from a geneticist explaining that, unfortunately, my blood sample showed that I had Lynch syndrome. Read more.

‘Why me? I had ovarian cancer at 14’
August 20, 2019: BBC News – When 14-year-old Kelliyah started experiencing severe abdominal pain, she initially blamed it on one too many fizzy drinks and a lack of exercise. She lived with the persistent symptoms for weeks before going to hospital. But once she did, doctors found a tumor the size of a pumpkin and, within 24 hours, Kelliyah was diagnosed with ovarian cancer. Doctors found a tumor weighing more than 5kg. Read more.

Nivolumab As Salvage Therapy Signals Response in Patients With Heavily Pretreated Gynecologic Cancers
August 19, 2019: Targeted Oncology – A retrospective study conducted at the Georgia Cancer Center in Augusta examined overall response and progression-free survival (PFS) in heavily pretreated patients with gynecologic malignancies who had received checkpoint inhibition therapy with nivolumab (Opdivo) in the salvage setting. Read more.

FDA announces international collaboration, approves pembrolizumab plus lenvatinib for endometrial cancer
September 17, 2019: Healio – The FDA, in conjunction with decisions by regulatory agencies in Australia and Canada, granted accelerated approval to pembrolizumab in combination with lenvatinib for the treatment of certain women with advanced endometrial carcinoma. Read more.

Expert Reviews Study Findings for Radical Hysterectomy in Cervical Cancer
September 11, 2019: Targeted Oncology – Sarah Ferguson, MD, discusses her experience being involved in a population-based study of women with cervical cancer treated with a radical hysterectomy. See More.

PTSD may increase risk for ovarian cancer
September 6, 2019: Healio – Symptoms of PTSD appeared associated with increased risk for ovarian cancer, especially among premenopausal women, according to study results published in Cancer Research. Read more,

Establishing Medical Fitness is the First Step in Treating Patients with Advanced Ovarian Cancer
August 26, 2019: Oncology Nursing News – Before considering intraperitoneal (IP) chemotherapy or dose-dense chemotherapy for a patient with newly diagnosed advanced ovarian cancer, their fitness should be established, said Jessica L. Berger, MD, as both approaches carry more toxicity than that of a standard weekly intravenous (IV) approach. Read more.

Case Review: Ovarian Cancer and the Initial Treatment Options
July 30, 2019: Targeted Oncology – Benedict Benigno, MD, discusses the case and treatment plan for a 58-year-old woman diagnosed with ovarian cancer. Read more.

Black Women With Cervical Cancer Less Likely to Receive Brachytherapy
July 29, 2019: Cancer Therapy Advisor – Black women with cervical cancer were less likely to receive brachytherapy and had poorer survival, suggesting brachytherapy may mediate survival outcomes. Read more.

Niraparib induces responses in late-line, BRCA-negative ovarian cancer
July 26, 2019: Healio – Niraparib demonstrated clinically relevant activity among women with heavily pretreated ovarian cancer, particularly those with homologous recombination deficiency-positive, platinum-sensitive disease, according to findings from the phase 2 QUADRA study published in The Lancet Oncology. Read more.

MD Anderson explains how to treat genetic mutations
July 24, 2019: KHOU – Dr. Pamela Soliman, Gynecologic Oncologist with MD Anderson Cancer Center, explains how to treat genetic mutations. Patient Yvonne Tate also shares her treatment story. Read more.

Collaborative Project Aims to Improve Care for Advanced Ovarian Cancer Patients
July 24, 2019: Ovarian Cancer News Today – A new collaborative project seeks to help ovarian cancer programs better understand and remove impediments to optimal care for patients with advanced epithelial disease. Called “Barriers to Quality Care in Ovarian Cancer,” the effort will be led by the Association of Community Cancer Centers (ACCC), along with AstraZeneca and Merck. Read more.

Ribociclib-Letrozole Regimen Tested in Ovarian, Endometrial Cancer
July 23, 2019: CancerNetwork – A phase II study found that the combination of ribociclib and letrozole showed promising activity in patients with estrogen receptor-positive ovarian cancer and endometrial cancer. The most benefit was observed in low-grade serous ovarian cancers. Read more.

Not Just Doctor’s Helpers: NPs and PAs Are Leaders in Cancer Care
July 23, 2019: Oncology Nursing News – When people picture the leaders of their cancer care, many may first think of oncologists or physicians. However, according to a recent study published in the Journal of the American Geriatrics Society, nurse practitioners actually comprised the largest group of providers for Medicare beneficiaries who received ambulatory care for any solid or hematologic malignancy. Read more.

Personalized Medicine Is the New Frontier in Ovarian Cancer
July 20, 2019: Oncology Nursing News – As new therapies such as PARP inhibitors have improved survival in patients with ovarian cancer, molecular testing is becoming more important, according to Jubilee Brown, MD. Read more.

Ontario study: Women undergoing minimally invasive procedures for early-stage cervical cancer had double the rates of death, recurrence
July 19, 2019: Cancer Letter – The population-based study, which included 958 cervical cancer patients who underwent minimally invasive between 2006 and 2017 in Ontario was designed to determine whether minimally invasive surgery is associated with adverse oncologic outcomes in cervical cancer patients. Read more.

Training for the Future: A Day in the Life of a Surgical Fellow
July 18, 2019: MSKCC – Emeline Aviki is a third-year gynecologic oncology fellow at MSK who is receiving advanced training in her field. Take a look inside her day. Read more.

US researchers study rucaparib in endometrial cancer patients
July 12, 2019: A research team at the University of Colorado Cancer Center (CU Cancer Center) in the US is set to lead a new clinical trial assessing poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib for the treatment of patients with endometrial cancer. Read more.

Doubled Risk of Death After MIS for Cervical Cancer: ‘Disturbing’
July 11, 2019: Medscape – Another blow has been dealt for minimally invasive surgery (MIS) in patients with cervical cancer — this time by Canadian researchers. Read more.

The cost of ’embarrassment’ when it comes to cervical cancer test
July 11, 2019: Sydney Morning Herald – According to a new survey from the Australian Cervical Cancer Foundation (ACCF), more than a quarter of Australian women say they are reluctant to book the Cervical Screening Test (CST, previously known as the Pap or smear test), with embarrassment or awkwardness around the procedure a major factor. Read more.

2 FOR 1 Smear tests could detect ovarian AND cervical cancer – as lack of ‘good’ vaginal bacteria ‘increases risk of deadly disease’
July 10, 2019: Sun – A drop in the number of lactobacilli present in the vagina significantly increased the risk of ovarian cancer, a new study found. Read more.

The Case for Tumor and Germline Testing in Endometrial Cancer Patients
June 27, 2019: CancerNetwork – A new study reinforces the need for universal mismatch repair (MMR) protein immunohistochemistry (IHC) screening of tumors from endometrial cancer patients, as well as germline genetic testing in accordance with the guidelines. Read more.

Breaking New Ground in the Treatment of Advanced Endometrial Cancer
June 19, 2019: CancerNetwork – In this interview, ONCOLOGY spoke with Vicky Makker, MD, a medical oncologist who treats patients with gynecologic cancers, including cervical, ovarian, and uterine tumors, about these options, as well as emerging combination therapies that are currently being evaluated in clinical trials. Read more.

Research Shows How Talc Powder May Change Ovarian Cancer Cells
June 18, 2019: Cancer Therapy Advisor –  In new research that was presented at the 2019 Annual Meeting of the Society of Gynecologic Oncology, Honolulu, Hawaii, Dr Saed’s team showed a link between talc and inflammation in normal and ovarian cancer cells. Read more.

After-cancer care: dealing with the long-term effects of cancer treatment
June 12, 2019: The Irish Times – Australian professor in Dublin to discuss infertility, early menopause and sexual problems. Read more.

Minimally invasive surgery linked to higher recurrence risk in early cervical cancer
June 7, 2019: Healio – Women who underwent minimally invasive surgery for early-stage cervical cancer demonstrated higher odds of recurrence than women who underwent open surgery, according to results of a multicenter retrospective study presented at ASCO Annual Meeting. Read more.

Olaparib prolongs PFS vs. chemotherapy in BRCA-mutated, platinum-sensitive ovarian cancer
June 7, 2019: Healio – Olaparib monotherapy significantly improved overall response rates and PFS, with no new safety signals, compared with nonplatinum chemotherapy among women with germline BRCA-mutated, platinum-sensitive relapsed ovarian cancer, according to results of the randomized phase 3 SOLO3 study presented at ASCO Annual Meeting. Read more.

Cervical Cancer During Pregnancy, Though Serious, is Highly Treatable According to New Research Review
June 4, 2019: News Wise – Over the years and with the publication of new studies, the treatment strategy has gradually changed to a more conservative treatment, particularly for patients in second or third trimester with early stage cancer. Read more.

Combo Therapy More Than Doubled PFS in Platinum-Sensitive Recurrent Ovarian Cancer
June 4, 2019: Cancer Network – The combination of the PARP inhibitor niraparib plus bevacizumab significantly improved progression-free survival in women with platinum-sensitive recurrent ovarian cancer. Read more.

Chemo-Free Doublet Significantly Improved PFS in Recurrent Ovarian Cancer
June 4, 2019: Targeted Oncology – The combination of niraparib (Zejula) and bevacizumab (Avastin) demonstrated a significant increase in progression-free survival (PFS) compared with niraparib alone in patients with platinum-sensitive recurrent ovarian cancer (PSROC), according to the results of the randomized ENGOT-OV24 trial. Read more.

Ovarian Cancer: Selecting Between Available PARPs
June 4, 2019:
Onc Live – Watch the video panel discussion.

Years of taking vitamin D appear to cut cancer death risk
June 4, 2019: Futurity – Vitamin D, if taken for at least three years, could help cancer patients live longer, say researchers. Read more.

NRG Oncology trial sets new standard regimen for women with uterine carcinosarcomas
June 2, 2019: Eureka Alert – The study concludes that among uterine cancer patients treatment with PC was not inferior to PI based on the primary objective overall survival (OS), and PC was associated with longer progression-free survival (PFS) outcomes when compared with PI. Read more.

Sexual Harassment in Training, Practice Reported by Two-Thirds of Gynecologic Oncologists
June 3, 2019: Targeted Oncology – Results from a survey conducted by the Society of Gynecologic Oncology (SGO) found that 70% of female and more than half of male gynecologic oncologists in the United States were victims of sexual harassment in either training or practice; and of those, only 10% said they reported their experiences. Read more.

FDA announces Expanded Access pilot program for oncology
June 3, 2019: Hem Onc Today – The FDA today announced a pilot project called OCE Project Facilitate aimed at allowing physicians to more easily navigate its Expanded Access program for investigational oncology treatments. Read more.

Tumor-infiltrating lymphocyte therapy appears safe, effective in melanoma, cervical cancer
June 2, 2019: Healio – Data from two trials evaluating the safety and efficacy of adoptive cell transfer with autologous tumor-infiltrating lymphocytes showed promising overall response rates for the treatment of advanced metastatic melanoma and cervical cancer, according to results presented at ASCO Annual Meeting. Read more.

5 Signs That Could Mean Ovarian Cancer–Early Stages Are Hard to Detect, Here’s How
May 27, 2019: The Epoch Times – Every year, roughly 21,000 people in the United States and 295,000 people worldwide are diagnosed with ovarian cancer. It’s the eighth-most common cancer for women globally, making up just under 4 percent of all cancer cases diagnosed in 2018. Read more.

Aggressive uterine cancer rising, particularly for black women
May 24, 2019: Axios – Women aged 30-70 — particularly black women — have been getting aggressive and deadly types of uterine cancer at higher rates in recent years, according to new research published by the National Cancer Institute earlier this week. Read more.

Deep Learning Model Can Predict Breast Cancer up to Five Years in Advance
May 24, 2019: Interesting Engineering – Researchers from MIT’s Computer Science and Artificial Intelligence Laboratory (CSAIL) and Massachusetts General Hospital (MGH) have created a new deep-learning model that can improve the early detection of breast cancer. Read more.

Research sheds new light on the function of frequently mutated cancer protein
May 24, 2019: News Medical –  According to the study, published online in Science Advances, ARID1A plays a role in the spatial organization of the genome; therefore, its loss has broad effects on global gene expression. This finding adds critical information towards deciphering the molecular alterations associated with several cancer types and especially with ovarian cancer. Read more.

FDA Grants Novel TIL Therapy Breakthrough Therapy Designation for Advanced Cervical Cancer
May 24, 2019: Targeted Oncology – The FDA has granted a breakthrough therapy designation to novel tumor-infiltrating lymphocyte therapy LN-145 for the treatment of patients with recurrent, metastatic, or persistent cervical cancer who have progressed on or after chemotherapy. Read more.

Predicting breast cancer metastasis by cell behavior instead of genetics
May 20, 2019: Medical Xpress – The test measures two key cell behaviors that are required for metastasis to occur: cell motility, the measure of how capable cells are of traveling to distant sites within the body, and proliferation, which is how much they are multiplying. Read more.

Case Report: Molecular Detection of Endometrial Precancer Using a Targeted Gynecologic Cancer Liquid Biopsy
May 17, 2019: Clinical Oncology – By using uterine lavage fluid for analysis, researchers provided the first demonstration that future, tumor-specific mutations can be identified in an asymptomatic woman without clinical or pathologic evidence of cancer. Read more.

Assessing the Benefit of Trebananib in Advanced Ovarian Cancer
May 16, 2019: Cancer Network – The angiogenesis inhibitor trebananib failed to improve outcomes over placebo when combined with carboplatin and paclitaxel in patients with advanced ovarian cancer, according to a phase III trial. Read more.

FDA Lifts Partial Hold on AIM2CERV Trial of Investigational Immunotherapy Agent in Cervical Cancer
May 15, 2019: Targeted Oncology – The FDA has lifted the partial clinical hold placed on the phase III AIM2CERV trial (NCT02853604), which is evaluating axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer, according to Advaxis, the developer of the investigational immunotherapy agent. Read more.

Vulval cancer: Woman undiagnosed for seven years
May 10, 2019: BBC – A County Down woman who has had surgery following vulval cancer is appealing to women to check themselves and be aware of changes in their genital area. Read more.

Research could lead to more precise diagnosis and treatment of ovarian cancer
May 8, 2019: Medical Xpress – Oncologists may soon have an accurate and inexpensive way of differentiating between types of ovarian cancer that will improve how patients are treated, thanks to findings from a national research study co-led out of the University of Alberta. Read more.

How Rwanda could be the first country to wipe out cervical cancer
May 7, 2019: Mosaic Science – The East African country’s campaign to end cervical cancer through the HPV vaccine has had to overcome cultural taboos and rumours about infertility – but it’s saving lives. Read more.

Pembrolizumab Provides Hope for PD-L1–Positive Cervical Cancer Patients
May 7, 2019: Cancer Network – Single-agent pembrolizumab showed durable clinical activity in patients with previously treated advanced cervical cancer enrolled on the phase II KEYNOTE-158 basket trial, and activity was higher among patients with programmed death-ligand 1 (PD-L1)–positive tumors (combined positive score [CPS] ≥1). The interim results were published in the Journal of Clinical Oncology. Read more.

Study Finds Synergism With Olaparib/Neratinib Combo in HER2+ Uterine Serous Carcinoma
May 6, 2019: Targeted Oncology – In new preclinical data, the combination of the PARP inhibitor olaparib (Lynparza) and the pan-HER TKI neratinib (Nerlynx) was found to be highly synergistic in HER2-positive uterine serous carcinoma, according to lead study author Ghanshyam Yadav, MD. Read more.

Screening for Human Papillomavirus in a Low- and Middle-Income Country
May 3, 2019: Journal of Global Oncology – This work demonstrates a deployable protocol for HPV screening in low- and middle-income countries with limited resources to perform cytopathology assessment of Pap smears. Read the article.

Study shows ovarian cancer survival increase
May 3, 2019: Medical Xpress – A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer—longer survival times plus a treatment option that causes fewer difficult side effects. Read more.

Changes in the metabolism of normal cells promotes the metastasis of ovarian cancer cells
May 1, 2019: Science Daily – A systematic examination of the tumor and the tissue surrounding it — particularly normal cells in that tissue, called fibroblasts — has revealed a new treatment target that could potentially prevent the rapid dissemination and poor prognosis associated with high-grade serous carcinoma (HGSC), a tumor type that primarily originates in the fallopian tubes or ovaries and spreads throughout the abdominal cavity. Read more.

Women with Ovarian Cancer Less Likely to Alert Providers As Symptoms Worsen
April 18, 2019: Oncology Nursing News – The more severe their symptoms, the less likely women with ovarian cancer are to report the discomforts to their oncologists, a study found. Read more.

Don’t Count on 23andMe to Detect Most Breast Cancer Risks, Study Warns
April 16, 2019: New York Times – A study of 100,000 people released earlier this month suggested that this experience could be widespread. Nearly 90 percent of participants who carried a BRCA mutation would have been missed by 23andMe’s test, geneticists found. Read more.

Positive results of regional perfusion chemotherapy for progressive and refractory ovarian cancer made public today
April 16, 2019: EIN Presswire -Hypoxic abdominal perfusion for progressive and refractory ovarian cancer is an effective therapy offering comparably long survival at good quality of life. Read more.

Urinary HPV DNA Testing Can Reach Additional Women
April 14, 2019: Precision Vaccinations – A new study evaluated an alternative HPV cervical cancer test for women who are reluctant to have a Pap Smear. Read more.

Language on Social Media Reveals Concerns of Patients with Ovarian Cancer
April 14, 2019: Oncology Nursing News – The language used on social media can reveal important clues about the perspectives, values, and needs of patients and caregivers affected by ovarian cancer, and a recent study of this data should be the first of many, according to a research team whose results were presented at the ONS 44th Annual Congress. Read more.

The HPV vaccine is important for preteens and teenagers. What about older women?
April 13, 2019: Washington Post – ‘Is Gardasil 9 right for me?” my patient asked during a recent office visit. Read more.

HPV rates are increasing among women under 40
April 12th, 2019: Futurity – Human papillomavirus infection rates are increasing in women born after 1980 who did not receive the HPV vaccine, research finds. Read more.

Socioeconomic barriers limit successful cervical cancer screening
April 12, 2019: Healio – Screening for cervical cancer has been a “great success,” according to a speaker at the American College of Physicians Internal Medicine Meeting. However, socioeconomic barriers prevent all women from gaining equal access to screening. Read more.

Saliva Tests Can Identify HPV16
April 11, 2019: Precision Vaccinations – Oral rinse samples have been found to contain reliable and reproducible HPV DNA data. Read more.

Loss of a DNA repair system creates a unique vulnerability in many cancer types
April 11, 2019: Science Daily –  Cancer cells that cannot repair a certain form of DNA mutation become strongly dependent on single enzyme to survive, creating a new potential opportunity for drug development. Read more.

What’s new in biomarker testing for ovarian cancer
April 10, 2019: Contemporary OB/GYN – Advances in biomarker discovery have led to several FDA-approved tests superior to CA125 in preoperative evaluation of women with a pelvic mass. Read more.

Ovarian cancer patients undertested for mutations that could guide clinical care
April 10, 2019: MD Linx – Fewer than a quarter of breast cancer patients and a third of ovarian cancer patients diagnosed between 2013 and 2014 in two states underwent genetic testing for cancer-associated mutations, according to a study by researchers at the Stanford University School of Medicine and several other organizations. Read more.

Does your gender influence your clinical decision-making?
April 09, 2019: MD Linx – Have you ever wondered whether male or female physicians take different approaches to patient care? Well, this certainly seems to be the case. Female physicians tend to take a more robust approach when deducing patient care, according to a recent study published in Gynecologic Oncology Reports. Read more.

3D ultrasound gives clinicians clearer picture to treat gynecological cancer
April 9, 2019: Eureka Alert – By transforming a conventional ultrasound probe, already found in most clinics, the technology can provide a 360-degree, three-dimensional view of surgical tools and surrounding tissue and organs. Read more.

Coleman Highlights Benefit With Maintenance Rucaparib Across Ovarian Cancer Subgroups
April 8, 2019: Targeted Oncology – In findings from the phase III ARIEL3 trial, maintenance therapy with the PARP inhibitor rucaparib (Rubraca) demonstrated an improvement in progression-free survival (PFS) in patients with platinum-sensitive recurrent ovarian cancer. Further analyses presented during the 2019 SGO Annual Meeting showed that this therapy is safe and effective across all subgroups of patients, regardless of age. Read more.

Cancer vaccine shows promising results in Lynch syndrome
April 8, 2019: Drug Target Review – Vaccination with as few as four tumour antigens generated antigen-specific responses, reduced intestinal tumours, and improved survival in a mouse model of Lynch syndrome, suggesting that it may be possible to develop a cancer preventive vaccine for patients with Lynch syndrome, according to data presented at the AACR Annual Meeting 2019 last week. Read more.

More Research is Needed to Prevent Late-Stage Diagnosis of Ovarian Cancer
April 8, 2019: Cure – Of the many challenges facing patients with ovarian cancer, one of the biggest is late-stage or delayed diagnosis due to the disease’s subtle signs and symptoms, according to Paula Anastasia RN, MN, AOCN. Read more.

Do Breast Cancer Patients Skip Follow-Up?
April 7, 2019: MedPage Today – Within the 5 years following a diagnosis for stage I or II breast cancer, 21% of patients stop seeing physicians for follow-up care, according to a study in the Journal of Oncology Practice. Read more.

New HPV Vaccine May Be Able to Treat Existing Infections and Cure Precancers
April 5, 2019: Health Central – In a clinical trial, researchers used the immune-based therapeutic injection on precancerous cells in the cervix, and one-third of the women treated were completely cured of the precancer and the underlying HPV infection. Read more.

Updates to Ovarian Cancer Guidelines Emphasize Importance of Germline, Somatic Testing
April 5, 2019: Targeted Oncology – Several bevacizumab (Avastin) combinations and the use of 3 FDA-approved PARP inhibitors have been introduced in the National Comprehensive Cancer Network (NCCN) guidelines for the treatment of patients with ovarian cancer. Based on these updates, the use of germline and somatic testing has become increasingly important in making treatment decisions for these patients. Read more.

Experimental therapy completely clears HPV in one-third of cervical cancer precursors
April 4, 2019: Medical Xpress – A potential new immune-based therapy to treat precancers in the cervix completely eliminated both the lesion and the underlying HPV infection in a third of women enrolled in a clinical trial. Read more.

Older women have the highest risk of dying from cervical cancer
April 3, 2019: Science Daily – New research shows that women aged 65 and older have a higher risk of dying from cervical cancer than previously thought — although this age group is not covered by the Danish screening program. Read more.

Study: The Pill May Protect Against Ovarian Cancer
April 3, 2019: WebMD – The protection that birth control pills offer against ovarian cancer is strongest with the most aggressive forms of the disease, a new study says. Read more.

Immune response worsens outcomes for African American patients with ovarian cancer, USA Health study finds
April 2, 2019: Alabama News Center – African American patients with advanced ovarian cancer were found to have a pre-existing immune response linked to worse survival rates compared with their white counterparts, according to research led by Dr. Rodney Rocconi, a gynecologic oncologist and interim director of the USA Health Mitchell Cancer Institute. Read more.

How Surgical Robot Assistants Are Becoming A Reality In Indian Hospitals And Healthcare Sector
April 2, 2019:
Analytics India Magazine – According to a 2018 study by a leading job portal, India witnessed a spike in the number of job seekers in the field of robotics by 186 per cent, whereas, job postings in the segment stood at 191 per cent. Read more.

ePRO Tool Improves Symptom Management in an Outpatient Gynecologic Cancer Clinic
April 1, 2019: Oncology Nurse Advisor – The Patient-Reported Outcomes Measurement Information System (PROMIS) Network, funded by the National Institutes of Health (NIH), was developed to be a collaborative effort to advance and standardize measurement of health-related quality of life (HRQOL) in clinical practice. Read more.

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer
April 1, 2019: MD Linx – In this phase II study, researchers examined the antitumor activity of nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors, in bevacizumab-resistant recurrent epithelial ovarian cancer (EOC), tubal, and peritoneal cancer. Read more.

Gynecology Experts Reflect on Precision Medicine Highlights From SGO Annual Meeting
March 29, 2019: Targeted Oncology -A common theme evident among the abstracts presented during the 2019 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held earlier this month in Honolulu, Hawaii, was matching the right treatment to the right patient at the right time, said Shannon Westin, MD, which is a foundation of precision medicine. Read more.

FDA proposes mammogram changes for first time in 20 years to identify breast cancer early
March 28, 2019: USA Today – The U.S. Food and Drug Administration proposed new rules Wednesday that will require mammogram centers to tell women more about how dense breast tissue can affect their health and increase their cancer risk. Read more.

Phase III Trial Launches to Investigate TTFields With Paclitaxel in Recurrent Ovarian Cancer
March 26, 2019: Targeted Oncology – A pivotal phase III INNOVATE-3 trial investigating the efficacy of tumor-treating fields (TTFields; Optune) combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer has been initiated, according to Novocure, the company developing the device. Read more.

Racial Disparities in Hospice Enrollment Persist in Ovarian Cancer
March 25, 2019: Cancer Network – Though many elderly patients with ovarian cancer enroll in hospice care, a substantial proportion subsequently unenroll and die without hospice, according to a new study. Black patients are more likely to unenroll than white patients. Read more.

Low White Blood Cell Count May Help Predict Some Ovarian Cancer Outcomes
March 22, 2019: Ovarian Cancer News Today – A reduced number of lymphocytes — one of the main types of immune cells — in advanced ovarian cancer patients before treatment is linked with a higher risk of disease worsening and shorter overall survival, according to a South Korean study. Read more.

Immunotherapy Improves Prognosis for Recurrent Ovarian Cancer Patients
March 21, 2019: Precision Vaccinations – Dendritic cell-based immunotherapy uses the patient’s own immune system to combat cancer and offers long-lasting antitumor immunity. Read more.

Cervical screening: DIY smear test could be ‘game-changer’
March 21, 2019: BBC News – Women are to be offered the chance to carry out smear tests at home in a bid to cut the rates of cervical cancer. Read more.

Evaluating Chemotherapy Plus Adjuvant Radiation Therapy for Vulvar Cancer
March 18, 2019: Cancer Therapy Advisor – Results of this retrospective study showed that adjuvant chemoradiation (CRT) did not significantly improve overall survival (OS) compared with adjuvant radiation therapy (RT) alone in women with squamous cell carcinoma of the vulva. Read more.

SGO 2019: Less Worry, More Symptoms and Regret With Risk-Reducing Salpingo-Oophorectomy
March 18, 2019: Cancer Network – Women at increased risked for hereditary ovarian cancer who underwent risk-reducing salpingo-oophorectomy experienced less worry but worse menopausal symptoms and more regret compared with those who underwent salpingectomy with delayed oophorectomy, the Women Choosing Surgical Prevention (WISP) trial reported (ClinicalTrials.gov Identifier: NCT02760849). Read more.

Carboplatin Desensitization Associated With Improved Overall Survival in Recurrent Ovarian Cancer
March 18, 2019: Cancer Therapy Advisor -Results from a retrospective study of patients with recurrent ovarian cancer treated with carboplatin chemotherapy showed that overall survival (OS) was significantly longer for patients treated with a carboplatin desensitization protocol (due to carboplatin hypersensitivity) compared with those who did not exhibit carboplatin hypersensitivity reactions. Read more.

Racial Differences in Immune Escape Mechanisms of Ovarian Cancer
March 18, 2019: Cancer Therapy Advisor – RNA expression of 5 genes involved in the indoleamine 2.3-dioxygenase (IDO) pathway, a marker of escape from immune control, was significantly upregulated in black patients with advanced ovarian cancer compared with matched white patients (P <.01). These findings were presented at the SGO 50th Annual Meeting on Women’s Cancer. Read more.

Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy
March 18, 2019: Cure – Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis of the ongoing ENGOT-OV26/PRIMA study. Read more.

Brachytherapy improves survival in advanced cervical cancer, but racial disparities remain
March 17, 2019: Healio – Black women —who have the highest cervical cancer mortality — are significantly less likely than white women to receive the boost as part of treatment. Read more.

PFS Increased With Niraparib Without Symptoms or Toxicity in Ovarian Cancer
March 17, 2019: Targeted Oncology – Treatment with maintenance niraparib (Zejula) led to extended progression-free survival (PFS) time in patients with recurrent ovarian cancer without the patients experiencing symptoms or toxicity compared with placebo, according to results of an analysis from the phase III ENGOT-OV16/NOVA trial. Read more.

Conservatively Managing Ovarian Tumors
March 10, 2019: ASCO Post – In an interim analysis of a prospective cohort study (IOTA5) reported in The Lancet Oncology, Wouter Froyman, MD, and colleagues found that the risk of malignancy and acute complications is low when adnexal masses with benign ultrasound findings are managed conservatively. Read more.

Moving Away From IP Chemotherapy in Advanced Ovarian Cancer
February 28, 2019: OncLive – Dr. Bradley Monk discusses the evolution of treatment of women with advanced-stage epithelial ovarian cancer. Read the article.

Lymphadenectomy fails to extend survival, linked to more complications in ovarian cancer
February 27, 2019: Healio – Systematic pelvic and paraaortic lymphadenectomy failed to improve survival among women with advanced ovarian cancer who underwent macroscopically complete resection and had normal lymph nodes before and during surgery, according to results from the randomized LION trial published in The New England Journal of Medicine. Read more.

New Grant Award Supports Research on Early Detection of Ovarian Cancer
February 26, 2019: Georgia Tech – Promising research toward what could become the first simple and accurate test for the early detection of ovarian cancer could be validated – and expanded – thanks to a significant grant from the Prevent Cancer Foundation. Read more.

Cervical cancer study suggests ‘global elimination is within reach’
February 26, 2019:  Healio – A rapid scale-up of HPV vaccination and screening could effectively eliminate cervical cancer as a major public health problem in most countries by 2100, according to a modelling study published in Lancet Oncology. Read more.

Patients’ HIV status should not impact their cancer care
February 25, 2019: Medical Xpress – New articles published in Cancer, a peer-reviewed journal of the American Cancer Society, note that there is no medical justification to deny optimal cancer therapy to individuals with HIV. Read more.

Could Conservative Management of Adnexal Masses Lead to Ovarian Cancer?
February 20, 2019: Cancer Network – “Our results suggest that the risk of malignancy and acute complications is low if adnexal masses with benign ultrasound morphology are managed conservatively,” the authors concluded. Read more.

Compound Could Help Treat Ovarian Cancer
February 20, 2019: Technology Networks – In the paper, published in the Journal of the American Chemical Society, scientists screened new compounds made in the lab against a “panel” of cancers that were sensitive and resistant to standard cancer therapy. Read more.

Breast Cancer Treatments Could Be Used for Rare Ovarian Cancer, Study Suggests
February 20, 2019: Ovarian Cancer News Today – Medications currently approved to treat some kinds of breast cancer — generally called CDK4/6 inhibitors — could be re-purposed to treat a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a study suggests. Read more.

Losartan May Improve Ovarian Cancer Treatment, Study Finds
February 11, 2019: Ovarian Cancer News Today – Losartan, a medicine used for treating high blood pressure, might improve ovarian cancer treatment by making it easier for chemotherapy drugs to get to tumor cells, a study found. Read more.

Minimally invasive cervical cancer surgery may promote disease recurrence; professionals urge patience
February 10, 2019: HemOnc Today spoke with gynecologic oncologists and surgeons about the results of these two studies, whether the data should have an immediate impact on clinical practice, what questions are left unanswered, and how surgeons should treat their patients before further conclusions are drawn. Read more.

Japanese study finds concerning trends in cervical cancer and treatment response
February 7, 2019: Medical Xpress –  Cervical cancer rates can be greatly reduced through preventive measures against the human papillomavirus (HPV) along with proactive cancer screening. Japan may be showing how ignoring that knowledge could prove hazardous, as it is the only advanced economy in which the cervical cancer rate is increasing. Read more.

Fallopian Tube Cancer Market Growth Opportunities by Regions, Scope, Key Players, Type and Application; Trend Forecast 2026
February 7, 2019: World Analytics – Key Market Dynamics of the Fallopian Tube Cancer Market Market report provides thorough forecasts on the latest market trends, development patterns, and research methodologies. Read more.

Where does Immune Checkpoint Inhibition fit in Advanced Ovarian Cancer Treatment
January 29, 2019: Cancer Network – The new study involved an expansion cohort from the phase I JAVELIN Solid Tumor trial, including a total of 125 patients with advanced ovarian cancer who had previously received chemotherapy including a platinum agent. Patients were treated with the anti–programmed death ligand 1 (PD-L1) agent avelumab at a dose of 10 mg/kg every 2 weeks. Read more.

Patients With Gynecologic Cancers Want to Discuss Sexual Health
January 25, 2019: Cure Today – Vaginal dryness, vaginal irritation, vaginal scar tissue, yeast infections and infertility are a few effects that patients can experience, all of which can affect intimate relations. However, these concerns are not always addressed by health care providers. Read more.

Avelumab demonstrates antitumor activity in ovarian cancer
January 24, 2019: Healio – Avelumab demonstrated antitumor activity and safety among heavily pretreated patients with recurrent or refractory ovarian cancer, according to results from the JAVELIN solid tumor study published in JAMA Oncology. Read more.

FDA places partial hold on phase 3 trial of axalimogene filolisbac for cervical cancer
January 24, 2019: HemOnc Today – The FDA placed a partial clinical hold on the ongoing randomized, double-blind, placebo-controlled AIM2CERV trial, which is evaluating axalimogene filolisbac in high-risk, locally advanced cervical cancer. Read more.

Scientists Discover New Potential Way To Stop Breast Cancer Spreading
January 21, 2019: Forbes – A new study published today in the journal Nature Cell Biology has uncovered a new way by which cells that have broken away from the original tumor (disseminated tumor cells) may hide in other parts of the body, evading therapy designed to eliminate them before they can grow into metastatic tumors. Read more.

Why Is Uterine Cancer on the Rise?
January 16, 2019: US News – Research indicates that the increase in obesity in the U.S. can be correlated with the rise in uterine cancer deaths. Read more.

Can AI Outperform Doctors at Detecting Cervical Cancer?
January 18, 2019: Cancer Network – A computer algorithm was able to accurately analyze digital images of cervical screenings and identify precancerous changes that required further medical follow-up, a new study showed. The new approach, called automated visual evaluation, has the potential to change point-of-care cervical screening. Read more.

Five updates in cervical cancer
January 11, 2019: Healio – Here are 5 articles related to advances in cervical cancer detection and treatment, new data on the role of HPV positivity, and the persistent underuse of HPV vaccination and cervical cancer screening. Read more.

Trial Failure Still Yields Insights for Uterine Leiomyosarcoma
January 10, 2019: Cancer Network – Acknowledging the small study population, Chapman-Davis concluded that the trial adds to the existing literature that supports observation as the standard of care in the adjuvant setting for patients with high-grade uterine leiomyosarcoma. Read more.

OncoSec and Gynecologic Oncology Group (GOG) Foundation, Inc. to Conduct a Pivotal Study of TAVO™ with Standard of Care KEYTRUDA® for Treatment of Late Stage Cervical Cancer
January 7, 2019: PRNewswire – In this registration-directed clinical trial, OncoSec and GOG will evaluate the combination of TAVO and commercially available KEYTRUDA with the goal of achieving a clinically meaningful response rate greater than what has already been demonstrated with KEYTRUDA alone (14%). Read more.

Exploring the feasibility of using mobile phones to improve the management of clients with cervical cancer precursor lesions
January 7, 2019: BMC Women’s Health – Cancer screening programs hold much potential for reducing the cervical cancer disease burden in developing countries. The aim of this study was to determine the feasibility of mobile health (mHealth) phone technology to improve management and follow-up of clients with cervical cancer precursor lesions. Read more.

Women With Select Subtypes of HPV at Higher Risk for Developing High-Grade Cervical Cancer
January 4, 2019: Targeted Oncology – The nested case-control Swedish study, published in Cancer, found that the presence of specific subtypes of HPV, namely HPV-16 and -18, were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia (CIN) in women under the age of 30. Read more.

Avelumab fails to extend PFS in ovarian cancer
January 2, 2019: Healio – A randomized phase 3 trial designed to evaluate avelumab for women with previously untreated advanced ovarian cancer failed to achieve its primary endpoint of PFS. Read more.